Journal Articles – Parkinson's Disease Center and Movement Disorders Clinic

Journal articles authored and co-authored by members of the Parkinson's Disease Center and Movement Disorders Clinic are listed here in reverse chronological order and grouped by published year. Click on the Expand plus symbol or Collapse minus symbol symbol to expand/collapse the list of journal publications by year, respectively.

Click on the PubMed link for details of that publication.

The cite count designates the number of times the publication has been cited by other papers indexed in Scopus. To access cite count information powered by Scopus, you must have a valid Texas Medical Center Resource Access Account. Need to register for access or forget password? Click here.

Sort By:    Year Published    Cite Count

2017

Collapse All | Expand All

Journal Articles Published in 2017 (n = 11)

Cite Count

PubMed

Reference

0     

Baizabal-Carvallo JF, Jankovic J. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017;264(2):359-63. PMID: 27942912.

0     

Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, et al. Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017;35:75-81. PMID: 28007518.

0     

Jankovic J, Squitieri F. Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2017;88(3):334. PMID: 28093514.

0     

Jankovic J. Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017;13(2):76-8. PMID: 28084323.

0     

Kanaan RA, Duncan R, Goldstein LH, Jankovic J, Cavanna AE. Are psychogenic non-epileptic seizures just another symptom of conversion disorder? J Neurol Neurosurg Psychiatry. 2017;:. PMID: 28235779.

0     

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, et al. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017;88(2):152-9. PMID: 27913695.

0     

Robledo I, Jankovic J. Media hype: Patient and scientific perspectives on misleading medical news. Mov Disord. 2017;:. PMID: 28370445.

0     

Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, et al. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017;74(2):216-24. PMID: 27942720.

0     

Thenganatt MA, Jankovic J. Psychogenic (functional) parkinsonism. Handb Clin Neurol. 2017;139:259-62. PMID: 27719845.

0     

Troster AI, Jankovic J, Tagliati M, Peichel D, Okun MS. Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017;32(3):433-40. PMID: 27753157.

0     

Vijayakumar D, Wijemanne S, Jankovic J. Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017;372:57-9. PMID: 28017248.

2016

Collapse All | Expand All

Journal Articles Published in 2016 (n = 35)

Cite Count

PubMed

Reference

0     

Alam M, Sanghera MK, Schwabe K, Lutjens G, Jin X, Song J, et al. Globus pallidus internus neuronal activity: a comparative study of linear and non-linear features in patients with dystonia or Parkinson's disease. J Neural Transm (Vienna). 2016;123(3):231-40. PMID: 26597125.

0     

Albanese A, Bhatia K, DeLong MR, Fahn S, Fung VS, Hallett M, et al. "Complex" dystonia is not a category in the new 2013 consensus classification. Mov Disord. 2016;31(11):1758-9. PMID: 27612445.

0     

Baizabal-Carvallo JF, Jankovic J. Functional (psychogenic) saccadic oscillations and oculogyric crises. Lancet Neurol. 2016;15(8):791. PMID: 27302355.

0     

Baizabal-Carvallo JF, Jankovic J. Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016;25:1-9. PMID: 26806438.

3

Baizabal-Carvallo JF, Jankovic J. Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016;12(3):175-85. PMID: 26891767.

0     

Baizabal-Carvallo JF, Jankovic J. Psychogenic ophthalmologic movement disorders. J Neuropsychiatry Clin Neurosci. 2016;28(3):195-8. PMID: 26792096.

0     

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, et al. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016;31(4):563-9. PMID: 26971359.

0     

Deeb W, Giordano JJ, Rossi PJ, Mogilner AY, Gunduz A, Judy JW, et al. Proceedings of the fourth annual deep brain stimulation think tank: A review of emerging issues and technologies. Front Integr Neurosci. 2016;10:38. PMID: 27920671.

0     

Deeb W, Rossi PJ, Porta M, Visser-Vandewalle V, Servello D, Silburn P, et al. The International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome: How Does It Work? Front Neurosci. 2016;10:170. PMID: 27199634.

0     

Deng HX, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016;48(7):733-9. PMID: 27270108.

0     

Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, et al. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016;22(7):590-8. PMID: 26886406.

0     

Farlow JL, Robak LA, Hetrick K, Bowling K, Boerwinkle E, Coban-Akdemir ZH, et al. Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016;73(1):68-75. PMID: 26595808.

0     

Huntington Study Group , Frank S, Testa CM, Stamler D, Kayson E, Davis C, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: A randomized clinical trial. Jama. 2016;316(1):40-50. PMID: 27380342.

0     

Huntington Study Group Pharos Investigators , Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, et al. Clinical-genetic associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for clinical trials. JAMA Neurol. 2016;73(1):102-10. PMID: 26569098.

0     

Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461-2470. PMID: 27819145.

0     

Jankovic J. Leg stereotypy disorder. J Neurol Neurosurg Psychiatry. 2016;87(2):220-1. PMID: 26209715.

0     

Jimenez-Shahed J, Telkes I, Viswanathan A, Ince NF. GPi Oscillatory Activity Differentiates Tics from the Resting State, Voluntary Movements, and the Unmedicated Parkinsonian State. Front Neurosci. 2016;10:436. PMID: 27733815.

0     

Jimenez-Shahed J. A review of current and novel levodopa formulations for the treatment of Parkinson's disease. Ther Deliv. 2016;7(3):179-91. PMID: 26893250.

0     

Kious BM, Jimenez-Shahed J, Shprecher DR. Treatment-refractory Tourette Syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:227-36. PMID: 26875502.

0     

LeDoux MS, Vemula SR, Xiao J, Thompson MM, Perlmutter JS, Wright LJ, et al. Clinical and genetic features of cervical dystonia in a large multicenter cohort. Neurol Genet. 2016;2(3):e69. PMID: 27123488.

0     

Lotia M, Jankovic J. Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol. 2016;36(1):54-63. PMID: 26866497.

1

Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016;17(7):895-909. PMID: 26830844.

0     

Mehanna R, Jimenez-Shahed J, Itin I. Three cases of levodopa-resistant parkinsonism after radiation therapy. Am J Case Rep. 2016;17:916-920. PMID: 27909286.

0     

Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, et al. Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry. Mov Disord Clin Pract. 2016;3(2):130-138. PMID: 27774495.

0     

Muller SH, Girard SL, Hopfner F, Merner ND, Bourassa CV, Lorenz D, et al. Genome-wide association study in essential tremor identifies three new loci. Brain. 2016;139(Pt 12):3163-9. PMID: 27797806.

0     

Oshima M, Deitiker P, Jankovic J, Atassi MZ. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016;300:36-46. PMID: 27806874.

0     

Pharos Investigators Huntington Study Group , Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016;73(1):102-10. PMID: 26569098.

0     

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-26. PMID: 27164716.

0     

Telkes I, Jimenez-Shahed J, Viswanathan A, Abosch A, Ince NF. Prediction of STN-DBS Electrode Implantation Track in Parkinson's Disease by Using Local Field Potentials. Front Neurosci. 2016;10:198. PMID: 27242404.

0     

Thenganatt MA, Jankovic J. Recent Advances in Understanding and Managing Tourette Syndrome. F1000Res. 2016;5:. PMID: 26918185.

0     

Thenganatt MA, Jankovic J. Response to Shill and colleagues. Parkinsonism Relat Disord. 2016;23:108. PMID: 26639977.

6

Thenganatt MA, Jankovic J. The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016;22 Suppl 1:S162-5. PMID: 26522219.

0     

Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016;76(7):759-77. PMID: 27091215.

0     

Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016;76(7):779-87. PMID: 27091214.

0     

Wijemanne S, Jankovic J, Evans RW. Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016;56(1):153-61. PMID: 26573884.

2015

Collapse All | Expand All

Journal Articles Published in 2015 (n = 32)

Cite Count

PubMed

Reference

0     

Ashoori A, Eagleman DM, Jankovic J. Effects of auditory rhythm and music on gait disturbances in Parkinson's disease. Front Neurol. 2015;6:234. PMID: 26617566.

4

Baizabal-Carvallo JF, Cardoso F, Jankovic J. Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015;30(2):171-9. PMID: 25487777.

3

Baizabal-Carvallo JF, Jankovic J. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015;262(11):2420-4. PMID: 26194199.

12

Baizabal-Carvallo JF, Jankovic J. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015;86(8):840-8. PMID: 25511790.

0     

Baizabal-Carvallo JF, Xia G, Botros P, Laguna J, Ashizawa T, Jankovic J. Bolivian kindred with combined spinocerebellar ataxia types 2 and 10. Acta Neurol Scand. 2015;132(2):139-42. PMID: 25630585.

0     

Byrne S, Walsh C, Hacohen Y, Muscal E, Jankovic J, Stocco A, et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e130. PMID: 26236759.

3

Calleo JS, Amspoker AB, Sarwar AI, Kunik ME, Jankovic J, Marsh L, et al. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015;28(3):210-7. PMID: 26047635.

4

Deng H, Wu Y, Jankovic J. The EIF4G1 gene and Parkinson's disease. Acta Neurol Scand. 2015;132(2):73-8. PMID: 25765080.

0     

Deng H, Xiu X, Jankovic J. Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol. 2015;51(3):1554-68. PMID: 25099932.

0     

Deng H, Zheng W, Jankovic J. Genetics and molecular biology of brain calcification. Ageing Res Rev. 2015;22:20-38. PMID: 25906927.

19

Feng Y, Jankovic J, Wu YC. Epigenetic mechanisms in Parkinson's disease. J Neurol Sci. 2015;349(1-2):3-9. PMID: 25553963.

5

Feng Y, Liu T, Dong SY, Guo YJ, Jankovic J, Xu H, et al. Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. J Neurochem. 2015;134(4):668-76. PMID: 25991017.

5

Jankovic J, Adler CH, Charles D, Comella C, Stacy M, Schwartz M, et al. Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE). J Neurol Sci. 2015;349(1-2):84-93. PMID: 25595221.

0     

Jankovic J, Bressman S, Dauer W, Kang UJ. Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015;30(14):1862-9. PMID: 26477883.

2

Jankovic J. Gait disorders. Neurol Clin. 2015;33(1):249-68. PMID: 25432732.

0     

Jankovic J. Movement disorders. Neurol Clin. 2015;33(1):xv-xvi. PMID: 25432734.

6

Jankovic J. Therapeutic Developments for Tics and Myoclonus. Mov Disord. 2015;30(11):1566-73. PMID: 26315614.

6

Jimenez-Shahed J. Design challenges for stimulation trials of Tourette's syndrome. Lancet Neurol. 2015;14(6):563-5. PMID: 25882028.

0     

Jost WH, Benecke R, Hauschke D, Jankovic J, Kanovsky P, Roggenkamper P, et al. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015;9:1913-26. PMID: 25897202.

16

Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015;30(3):313-27. PMID: 25649017.

19

Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710-9. PMID: 26025783.

15

Olanow CW, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015;78(2):248-57. PMID: 26061140.

0     

 

Relja M, Jacinto J, Jankovic J, Albanese A. Botulinum neurotoxin revisited - An individualised, patient-centric approach for the treatment of dystonia and spasticity. Euro Neurol Rev. 2015;10(1):28-34.

0     

Schuff N, Wu IW, Buckley S, Foster ED, Coffey CS, Gitelman DR, et al. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015;30(14):1885-92. PMID: 26260437.

0     

Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, et al. Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord. 2015;30(10):1371-81. PMID: 26095202.

6

Thenganatt MA, Jankovic J. Psychogenic movement disorders. Neurol Clin. 2015;33(1):205-24. PMID: 25432730.

5

Waln O, Jankovic J. Paroxysmal movement disorders. Neurol Clin. 2015;33(1):137-52. PMID: 25432727.

0     

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015;30(7):919-27. PMID: 25737166.

0     

Wijemanne S, Jankovic J. Dopa-responsive dystonia-clinical and genetic heterogeneity. Nat Rev Neurol. 2015;11(7):414-24. PMID: 26100751.

3

Wijemanne S, Jankovic J. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015;86(8):825-32. PMID: 25411548.

5

Wijemanne S, Jankovic J. Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015;16(6):678-690. PMID: 25979181.

11

Yu D, Mathews CA, Scharf JM, Neale BM, Davis LK, Gamazon ER, et al. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015;172(1):82-93. PMID: 25158072.

<2014

Collapse All | Expand All

Journal Articles Published in <2014 (n = 885)

Cite Count

PubMed

Reference

0     

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Reply: dystonia after severe head injuries. Mov Disord. 2014;29(4):578-9. PMID: 24590449.

0     

Baizabal-Carvallo JF, Jankovic J. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014;17(1):104-6. PMID: 23663196.

14

Baizabal-Carvallo JF, Jankovic J. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014;85(5):573-5. PMID: 24259592.

20

Baizabal-Carvallo JF, Kagnoff MN, Jimenez-Shahed J, Fekete R, Jankovic J. The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014;85(5):567-72. PMID: 24096713.

0     

Black KJ, Jankovic J, Hershey T, McNaught KS, Mink JW, Walkup J. Progress in research on Tourette syndrome. J Obsessive Compuls Relat Disord. 2014;3(4):359-62. PMID: 25436182.

7

Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams A, et al. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014;261(7):1309-19. PMID: 24752807.

27

Deng H, Gao K, Jankovic J. The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol. 2014;10(6):337-48. PMID: 24840975.

2

DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014;17(5):405-18; discussion 418. PMID: 24947418.

7

Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin(R)) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014;346(1-2):116-20. PMID: 25186131.

7

Evidente VGH, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014;346(1-2):116-20. PMID: 25186131.

0     

Factor SA, Jankovic J. Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics. 2014;11(1):3-5. PMID: 24366609.

1

Factor SA, Jankovic J. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014;83(15):1388-9. PMID: 25288700.

10

Feng Y, Liu T, Li XQ, Liu Y, Zhu XY, Jankovic J, et al. Neuroprotection by Orexin-A via HIF-1alpha induction in a cellular model of Parkinson's disease. Neurosci Lett. 2014;579:35-40. PMID: 25038418.

0     

Fernandez HH, Jankovic J, Holds JB, Lin D, Burns J, Verma A, et al. Observational Study of IncobotulinumtoxinA for Cervical Dystonia or Blepharospasm (XCiDaBLE): Interim Results for the First 170 Subjects with Blepharospasm. Tremor Other Hyperkinet Mov (N Y). 2014;4:238. PMID: 25120942.

7

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, et al. Designing clinical trials for dystonia. Neurotherapeutics. 2014;11(1):117-27. PMID: 24282121.

0     

Giladi N, Ghys L, Surmann E, Boroojerdi B, Jankovic J. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014;20(12):1345-51. PMID: 25444083.

0     

 

Gilbert DL, Jankovic J. Pharmacological treatment of Tourette syndrome. J Obsessive-Compulsive Relat Disord. 2014;3(4):407-14. DOI: 10.1016/j.jocrd.2014.04.006.

6

Goldman SM, Kamel F, Ross GW, Jewell SA, Marras C, Hoppin JA, et al. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014;29(9):1171-80. PMID: 24838182.

8

Hauser RA, Isaacson S, Clinch T, Tigan/Apokyn Study Investigators. Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. Parkinsonism Relat Disord. 2014;20(11):1171-6. PMID: 25239603.

0     

Hershey LA, Aggarwal R, Jindal P, Baranskaya I. Managing agitation in Alzheimer disease and related disorders. JSM Alzheimer's Dis Related Dementia. 2014;1(2):1007.

0     

Inzelberg R, Hassin-Baer S, Jankovic J. Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol. 2014;71(12):1567-72. PMID: 25347348.

6

Jankovic J, Berkovich E, Eyal E, Tolosa E. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014;20(6):640-3. PMID: 24637126.

5

Jankovic J, Roos RA. Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord. 2014;29(11):1414-8. PMID: 25156927.

5

Jankovic J, Sherer T. The future of research in Parkinson disease. JAMA Neurol. 2014;71(11):1351-2. PMID: 25178587.

6

Jankovic J. "Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord. 2014;29(13):1697-8. PMID: 25255973.

23

Le W, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics. 2014;11(1):92-110. PMID: 24158912.

14

McGrath LM, Yu D, Marshall C, Davis LK, Thiruvahindrapuram B, Li B, et al. Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014;53(8):910-9. PMID: 25062598.

4

Nutt JG, Siderowf AD, Guttman M, Schmidt PN, Zamudio JI, Wu SS, et al. Mobility, mood and site of care impact health related quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2014;20(3):274-9. PMID: 24182524.

27

Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014;20(2):142-8. PMID: 24055014.

0     

Parkinson Study Group QE Investigators , Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-52. PMID: 24664227.

3

Patel AJ, Sarwar AI, Jankovic J, Viswanathan A. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg. 2014;82(1-2):241 e1-4. PMID: 24076056.

3

Patel N, Hanfelt J, Marsh L, Jankovic J, members of the Dystonia Coalition. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014;85(8):882-4. PMID: 24828895.

49

Patel N, Jankovic J, Hallett M. Sensory aspects of movement disorders. Lancet Neurol. 2014;13(1):100-12. PMID: 24331796.

1

Patel N, Jimenez-Shahed J. Simultaneous improvement of tics and parkinsonism after pallidal DBS. Parkinsonism Relat Disord. 2014;20(9):1022-3. PMID: 24957594.

4

Patel N, Ondo W, Jimenez-Shahed J. Habituation and rebound to thalamic deep brain stimulation in long-term management of tremor associated with demyelinating neuropathy. Int J Neurosci. 2014;124(12):919-25. PMID: 24552416.

0     

Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD study. Front Aging Neurosci. 2014;6(APR):. PMID: 24795630.

7

Pulliam CL, Eichenseer SR, Goetz CG, Waln O, Hunter CB, Jankovic J, et al. Continuous in-home monitoring of essential tremor. Parkinsonism Relat Disord. 2014;20(1):37-40. PMID: 24126021.

18

Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014;90:344-8. PMID: 25130293.

57

Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499-504. PMID: 24514863.

0     

Thenganatt MA, Jankovic J. Psychogenic tremor: a video guide to its distinguishing features. Tremor Other Hyperkinet Mov (N Y). 2014;4:253. PMID: 25243097.

15

Thenganatt MA, Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11(1):139-52. PMID: 24142590.

15

van der Marck MA, Klok MP, Okun MS, Giladi N, Munneke M, Bloem BR, et al. Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. Parkinsonism Relat Disord. 2014;20(4):360-9. PMID: 24484618.

3

Waln O, Jimenez-Shahed J. Rechargeable deep brain stimulation implantable pulse generators in movement disorders: patient satisfaction and conversion parameters. Neuromodulation. 2014;17(5):425-30; discussion 430. PMID: 24112630.

4

Wijemanne S, Jimenez-Shahed J. Improvement in dystonic camptocormia following botulinum toxin injection to the external oblique muscle. Parkinsonism Relat Disord. 2014;20(10):1106-7. PMID: 24981917.

13

Wijemanne S, Wu LJ, Jankovic J. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014;29(1):126-30. PMID: 24150997.

3

Zhu XY, Pan TH, Ondo WG, Jimenez-Shahed J, Wu YC. Effects of deep brain stimulation in relatively young-onset multiple system atrophy Parkinsonism. J Neurol Sci. 2014;342(1-2):42-4. PMID: 24831987.

0     

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-73. PMID: 23649720.

20

Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna). 2013;120(11):1579-89. PMID: 23580159.

7

Baizabal-Carvallo JF, Jankovic J, Feld J. Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013;24(2):298-306. PMID: 23677449.

42

Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013;28(4):543-7. PMID: 23400857.

59

Davis LK, Yu D, Keenan CL, Gamazon ER, Konkashbaev AI, Derks EM, et al. Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013;9(10):e1003864. PMID: 24204291.

0     

Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive Epidemiology of Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 24255801.

17

Deng H, Gao K, Jankovic J. The VPS35 gene and Parkinson's disease. Mov Disord. 2013;28(5):569-75. PMID: 23536430.

19

Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013;70(1):20-4. PMID: 23318512.

8

Dhungana S, Jankovic J. Yips and other movement disorders in golfers. Mov Disord. 2013;28(5):576-81. PMID: 23519739.

0     

Fernandez HH, Pagan F, Danisi F, Greeley D, Jankovic J, Verma A, et al. Prospective study evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm: Interim results from the first 145 subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23724362.

0     

Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, et al. Efficacy and safety of incobotulinumtoxinA in subjects previously treated with botulinum toxin versus toxin-naive subjects with cervical dystonia. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23610743.

54

Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114. PMID: 23380701.

0     

Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001-12. PMID: 23893456.

0     

 

Jimenez-Shahed J, Jankovic J. Tetrabenazine for treatment of chorea associated with Huntington's disease and other potential indications. Expert Opin Orphan Drugs. 2013;1(5):423-36. DOI: 10.1517/21678707.2013.787358.

6

Kansara S, Trivedi A, Chen S, Jankovic J, Le W. Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm (Vienna). 2013;120(1):197-210. PMID: 22733089.

25

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, et al. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013;80(22):2022-7. PMID: 23624566.

0     

Louis ED, Bain PG, Hallett M, Jankovic J, Vonsattel JP. What is It? Difficult to Pigeon Hole Tremor: a Clinical-Pathological Study of a Man with Jaw Tremor. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23864988.

9

Mehanna R, Hunter C, Davidson A, Jimenez-Shahed J, Jankovic J. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013;28(2):210-5. PMID: 23280482.

44

Mehanna R, Jankovic J. Movement disorders in cerebrovascular disease. Lancet Neurol. 2013;12(6):597-608. PMID: 23602779.

14

Mehanna R, Jankovic J. Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013;328(1-2):1-8. PMID: 23522528.

0     

Mehanna R, Jankovic J. Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol. 2013;12(8):734-5. PMID: 23867192.

29

Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141-52. PMID: 23178324.

18

Ramirez-Castaneda J, Jankovic J, Comella C, Dashtipour K, Fernandez HH, Mari Z. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013;28(13):1775-83. PMID: 23868503.

30

Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013;5(2):249-66. PMID: 23381141.

57

Scharf JM, Yu D, Mathews CA, Neale BM, Stewart SE, Fagerness JA, et al. Genome-wide association study of Tourette's syndrome. Mol Psychiatry. 2013;18(6):721-8. PMID: 22889924.

0     

Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol. 2013;11(1):59-79. PMID: 23814539.

0     

Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and Efficacy of Tetrabenazine and Use of Concomitant Medications During Long-Term, Open-Label Treatment of Chorea Associated with Huntington's and Other Diseases. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 24255799.

54

Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013;28(5):668-70. PMID: 23408503.

3

Strickland BA, Jimenez-Shahed J, Jankovic J, Viswanathan A. Radiofrequency lesioning through deep brain stimulation electrodes: a pilot study of lesion geometry and temperature characteristics. J Clin Neurosci. 2013;20(12):1709-12. PMID: 24035651.

15

Truong DD, Gollomp SM, Jankovic J, LeWitt PA, Marx M, Hanschmann A, et al. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin((R))) injections in blepharospasm. J Neural Transm (Vienna). 2013;120(9):1345-53. PMID: 23435927.

0     

Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:. PMID: 23858394.

3

Waln O, Jankovic J. Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord. 2013;28(8):1162-3. PMID: 23580321.

7

Waln O, Jankovic J. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013;28(12):1748-9. PMID: 23637028.

13

Atassi MZ, Jankovic J, Steward LE, Aoki KR, Dolimbek BZ. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012;217(1):17-27. PMID: 21962573.

25

Baizabal Carvallo JF, Mostile G, Almaguer M, Davidson A, Simpson R, Jankovic J. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012;90(5):300-6. PMID: 22797749.

3

Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord. 2012;27(8):935-46. PMID: 22555904.

1

Baizabal-Carvallo JF, Jankovic J. Spinocerebellar ataxia types 2 and 10: more than a coincidental association? Arch Neurol. 2012;69(11):1524-5; Author reply 1525. PMID: 23117922.

48

Deng H, Gao K, Jankovic J. The genetics of Tourette syndrome. Nat Rev Neurol. 2012;8(4):203-13. PMID: 22410579.

16

Deng H, Gu S, Jankovic J. LINGO1 variants in essential tremor and Parkinson's disease. Acta Neurol Scand. 2012;125(1):1-7. PMID: 21470193.

74

Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46(1):1-18. PMID: 22266337.

18

Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, et al. Reliability of a new scale for essential tremor. Mov Disord. 2012;27(12):1567-9. PMID: 23032792.

28

Elmer LW, Surmann E, Boroojerdi B, Jankovic J. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012;18(5):488-93. PMID: 22326237.

16

Fekete R, Baizabal-Carvallo JF, Ha AD, Davidson A, Jankovic J. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012;83(2):202-4. PMID: 21949106.

0     

Fekete R, Jankovic J. Childhood stiff-person syndrome improved with rituximab. Case Rep Neurol. 2012;4(2):92-6. PMID: 22740823.

10

Goldman SM, Kamel F, Ross GW, Jewell SA, Bhudhikanok GS, Umbach D, et al. Head injury, alpha-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012;71(1):40-8. PMID: 22275250.

3

Guo Y, Deng X, Jankovic J, Su L, Zhang J, Le W, et al. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012;526(2):150-3. PMID: 22917605.

55

Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord. 2012;27(4):485-91. PMID: 21953990.

72

Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol. 2012;25(4):433-47. PMID: 22691758.

1

Jankovic J. Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012;25(4):429-32. PMID: 22772873.

0     

Jimenez-Shahed J. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin(R)), a botulinum neurotoxin type A free from complexing proteins. Neuropsychiatr Dis Treat. 2012;8:13-25. PMID: 22275842.

18

Kurlan R, Crespi G, Coffey B, Mueller-Vahl K, Koval S, Wunderlich G, et al. A multicenter randomized placebo-controlled clinical trial of pramipexole for Tourette's syndrome. Mov Disord. 2012;27(6):775-8. PMID: 22407510.

120

Lee HY, Huang Y, Bruneau N, Roll P, Roberson EDO, Hermann M, et al. Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012;1(1):2-12. PMID: 22832103.

37

Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, et al. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012;27(2):284-8. PMID: 22161845.

6

Li XP, Xie WJ, Zhang Z, Kansara S, Jankovic J, Le WD. A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals. 2012;20(4):223-36. PMID: 22269801.

10

Marshall DF, Strutt AM, Williams AE, Simpson RK, Jankovic J, York MK. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012;19(12):1525-31. PMID: 22632922.

8

Mehanna R, Jankovic J. Respiratory disorders associated with dystonia. Mov Disord. 2012;27(14):1816-9. PMID: 23208724.

11

Mostile G, Fekete R, Giuffrida JP, Yaltho T, Davidson A, Nicoletti A, et al. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012;18(7):859-63. PMID: 22591578.

129

Okun MS, Gallo BV, Mandybur G, Jagid J, Foote KD, Revilla FJ, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012;11(2):140-9. PMID: 22239915.

6

Ondo WG, Hunter C, Ferrara JM, Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord. 2012;18(5):619-22. PMID: 22284728.

9

Ondo WG, Jankovic J, Simpson R, Jimenez-Shahed J. Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012;13(9):1202-4. PMID: 22995627.

19

Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650-4. PMID: 22573627.

21

Pan T, Zhu J, Hwu WJ, Jankovic J. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012;7(9):. PMID: 23028833.

0     

Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, et al. Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370-84. PMID: 22451204.

9

Patel SS, Jankovic J, Hood AJ, Jeter CB, Sereno AB. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012;313(1-2):35-41. PMID: 22018763.

32

Poewe W, Mahlknecht P, Jankovic J. Emerging therapies for Parkinson's disease. Curr Opin Neurol. 2012;25(4):448-59. PMID: 22772874.

14

Squitieri F, Jankovic J. Huntington's disease: how intermediate are intermediate repeat lengths? Mov Disord. 2012;27(14):1714-7. PMID: 23008174.

22

Strutt AM, Simpson R, Jankovic J, York MK. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012;19(1):121-7. PMID: 21668586.

27

Viswanathan A, Jimenez-Shahed J, Baizabal Carvallo JF, Jankovic J. Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012;90(4):213-24. PMID: 22699684.

14

Zhang Z, Li X, Xie W, Tuo H, Hintermann S, Jankovic J, et al. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease. CNS Neurol Disord Drug Targets. 2012;11(6):768-73. PMID: 22483304.

12

Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011;216(7):782-92. PMID: 21281977.

21

Baizabal Carvallo JF, Simpson R, Jankovic J. Diagnosis and treatment of complications related to deep brain stimulation hardware. Mov Disord. 2011;26(8):1398-406. PMID: 21714001.

13

Baizabal-Carvallo JF, Jankovic J, Pappert E. Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011;58(1):1-7. PMID: 21620881.

42

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, US Xeomin Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-9. PMID: 21764407.

42

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN ®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011;308(1-2):103-9. PMID: 21764407.

7

Deitiker PR, Oshima M, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011;44(3):167-76. PMID: 20843162.

39

Fekete R, Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. 2011;26(3):391-8. PMID: 21462256.

10

Ferrara J, Stamey W, Strutt AM, Adam OR, Jankovic J. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011;23(2):141-8. PMID: 21677241.

8

Guo Y, Jankovic J, Song Z, Yang H, Zheng W, Le W, et al. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011;487(2):174-6. PMID: 20951767.

14

Guo Y, Le WD, Jankovic J, Yang HR, Xu HB, Xie WJ, et al. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011;26(9):1729-32. PMID: 21469209.

35

Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011;17(8):625-8. PMID: 21689962.

1

Ha AD, Jankovic J. An introduction to dyskinesia--the clinical spectrum. Int Rev Neurobiol. 2011;98:1-29. PMID: 21907081.

21

Ha AD, Jankovic J. Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011;123(5):116-21. PMID: 21904093.

1

Ha AD, Jankovic J. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011;26(8):1556-8. PMID: 21495070.

21

Heldman DA, Jankovic J, Vaillancourt DE, Prodoehl J, Elble RJ, Giuffrida JP. Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011;17(7):537-42. PMID: 21570891.

145

Hoglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011;43(7):699-705. PMID: 21685912.

9

Jankovic J, Adler CH, Charles PD, Comella C, Stacy M, Schwartz M, et al. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011;11:140. PMID: 22054223.

49

Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509-23. PMID: 22014129.

27

Jankovic J, Comella C, Hanschmann A, Grafe S. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521-8. PMID: 21520284.

89

Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011;26(6):1149-56. PMID: 21484868.

0     

Jankovic J, Yeeles K, Katsakou C, Amos T, Morriss R, Rose D, et al. Family caregivers' experiences of involuntary psychiatric hospital admissions of their relatives--a qualitative study. PLoS One. 2011;6(10):e25425. PMID: 22022393.

16

Jankovic J. Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry. 2011;82(12):1300-3. PMID: 21933950.

0     

Kieburtz K, Parkinson Study Group PramiBID Investigators. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord. 2011;26(1):37-44. PMID: 20925067.

18

Le W, Nguyen D, Lin XW, Rawal P, Huang M, Ding Y, et al. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2011;32(4):750-3. PMID: 19394114.

43

Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm. 2011;118(3):473-7. PMID: 21161300.

0     

Nopoulos PC, Aylward EH, Ross CA, Mills JA, Langbehn DR, Johnson HJ, et al. Smaller intracranial volume in prodromal Huntington's disease: evidence for abnormal neurodevelopment. Brain. 2011;134(Pt 1):137-42. PMID: 20923788.

6

Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, et al. Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. Parkinsonism Relat Disord. 2011;17(2):117-8. PMID: 21084213.

5

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011;240-241:121-8. PMID: 22079193.

8

Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011;237(1-2):66-72. PMID: 21737146.

47

Pan T, Li X, Jankovic J. The association between Parkinson's disease and melanoma. Int J Cancer. 2011;128(10):2251-60. PMID: 21207412.

0     

Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, et al. Copy number variation in familial Parkinson disease. PLoS One. 2011;6(8):e20988. PMID: 21829596.

149

Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol. 2011;95(4):629-35. PMID: 21930184.

31

Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147-52. PMID: 20818603.

90

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011;10(5):415-23. PMID: 21482191.

165

Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011;69(3):570-80. PMID: 21400565.

9

Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011;26(5):925-7. PMID: 21370274.

39

van Rooijen DE, Geraedts EJ, Marinus J, Jankovic J, van Hilten JJ. Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011;82(8):892-8. PMID: 21493756.

33

Wang Y, Hancock AM, Bradner J, Chung KA, Quinn JF, Peskind ER, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011;178(4):1509-16. PMID: 21435440.

31

Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011;17(5):321-7. PMID: 21316292.

66

Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011;68(1):22-30. PMID: 21220674.

124

Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011;19(3):163-74. PMID: 21778691.

8

Yaltho TC, Jankovic J, Lotze T. The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011;26(2):359-60. PMID: 21412842.

37

Yaltho TC, Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord. 2011;26(9):1582-92. PMID: 21469208.

0     

Anderson KE, Gehl CR, Marder KS, Beglinger LJ, Paulsen JS, Huntington's Study Group. Comorbidities of obsessive and compulsive symptoms in Huntington's disease. J Nerv Ment Dis. 2010;198(5):334-8. PMID: 20458194.

0     

Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS, et al. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178(2):414-8. PMID: 20471695.

10

Deng H, Yang H, Le W, Deng X, Xu H, Xiong W, et al. Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010;392(4):548-50. PMID: 20097173.

1

Deng S, Deng H, Le W, Xu H, Yang H, Deng X, et al. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010;468(3):195-7. PMID: 19879328.

22

DiLorenzo DJ, Jankovic J, Simpson RK, Takei H, Powell SZ. Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010;25(2):232-8. PMID: 20063387.

0     

Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, et al. Mild cognitive impairment in prediagnosed Huntington disease. Neurology. 2010;75(6):500-7. PMID: 20610833.

0     

Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B, et al. Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease. Mov Disord. 2010;25(8):1082-6. PMID: 20131372.

0     

Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, et al. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord. 2010;16(6):423-6. PMID: 20338800.

13

Fekete R, Jankovic J. Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010;25(4):503-4. PMID: 20063405.

17

Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81(3):315-9. PMID: 19726415.

33

Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs. 2010;70(5):561-71. PMID: 20329804.

0     

Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM, et al. Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). Mov Disord. 2010;25(9):1190-4. PMID: 20629138.

261

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010;133(Pt 3):713-26. PMID: 20157014.

43

Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010;29(1):79-125. PMID: 19358229.

23

Jankovic J, Gelineau-Kattner R, Davidson A. Tourette's syndrome in adults. Mov Disord. 2010;25(13):2171-5. PMID: 20690167.

63

Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70-3. PMID: 19726418.

39

Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of parkinsonian deformities. Mov Disord. 2010;25(5):527-8. PMID: 20425791.

18

Kuo SH, Jimenez-Shahed J. Topiramate in treatment of tourette syndrome. Clin Neuropharmacol. 2010;33(1):32-4. PMID: 19935407.

0     

Langbehn DR, Hayden MR, Paulsen JS, Predict-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397-408. PMID: 19548255.

0     

Li C, Guo Y, Xie W, Li X, Jankovic J, Le W. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. Neurochem Res. 2010;35(10):1546-56. PMID: 20635141.

10

Lim J, Sanghera MK, Darbin O, Stewart RM, Jankovic J, Simpson R. Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients. Exp Neurol. 2010;224(2):542-4. PMID: 20653074.

245

Marks WJ, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol. 2010;9(12):1164-72. PMID: 20970382.

41

Mehanna R, Jankovic J. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010;16(10):628-38. PMID: 20674459.

21

Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010;10(6):893-901. PMID: 20518606.

85

Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, et al. CSF A?42 and tau in Parkinson's disease with cognitive impairment. Movement Disorders. 2010;25(15):2682-5. PMID: 20818673.

21

Mostile G, Giuffrida JP, Adam OR, Davidson A, Jankovic J. Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010;25(12):1938-43. PMID: 20623687.

26

Mostile G, Jankovic J. Alcohol in essential tremor and other movement disorders. Mov Disord. 2010;25(14):2274-84. PMID: 20721919.

0     

Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, et al. Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis. 2010;40(3):544-54. PMID: 20688164.

6

Okun MS, Lang A, Jankovic J. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010;25(7):961-2; author reply 962-3. PMID: 20461816.

16

Ondo WG, Adam OR, Jankovic J, Chinnery PF. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010;25(14):2470-2. PMID: 20818611.

0     

Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3-4):201-7. PMID: 20385209.

0     

Paulsen JS, Wang C, Duff K, Barker R, Nance M, Beglinger L, et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord. 2010;25(15):2595-603. PMID: 20623772.

0     

Quaid KA, Swenson MM, Sims SL, Harrison JM, Moskowitz C, Stepanov N, et al. What were you thinking?: individuals at risk for Huntington Disease talk about having children. J Genet Couns. 2010;19(6):606-17. PMID: 20734119.

0     

Schwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, et al. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010;25(12):1801-8. PMID: 20669311.

60

Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, Yearout D, et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010;480(1):78-82. PMID: 20540987.

0     

Simon DK, Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, et al. Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. BMC Med Genet. 2010;11:53. PMID: 20356410.

156

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18-27. PMID: 20582993.

52

Tan EK, Peng R, Teo YY, Tan LC, Angeles D, Ho P, et al. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010;31(5):561-8. PMID: 20186690.

54

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010;16(5):316-23. PMID: 20359934.

63

Vilarino-Guell C, Wider C, Ross OA, Jasinska-Myga B, Kachergus J, Cobb SA, et al. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010;11(4):401-8. PMID: 20369371.

18

Wu Y, Davidson AL, Pan T, Jankovic J. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010;298(1-2):61-3. PMID: 20864122.

43

Wu Y, Li X, Xie W, Jankovic J, Le W, Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010;57(3):198-205. PMID: 20546814.

47

Xie W, Li X, Li C, Zhu W, Jankovic J, Le W. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease. J Neurochem. 2010;115(1):188-99. PMID: 20649845.

0     

York MK, Wilde E, Simpson R, Jankovic J. Acknowledgement of technological limitations while moving literature forward. J Neurol Sci. 2010;292(1-2):120. PMID: 20199780.

31

Zhu W, Li X, Xie W, Luo F, Kaur D, Andersen JK, et al. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010;37(2):307-13. PMID: 19818853.

6

Adam OR, Ferrara JM, Aguilar Tabora LG, Nashatizadeh MM, Negoita M, Jankovic J. Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology. 2009;73(10):e50-2. PMID: 19738167.

8

Adam OR, Ferrara JM, Jankovic J. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009;24(13):2030-2. PMID: 19672987.

0     

 

Albanese A, Bigalke H, Foster K, Hallett M, Jankovic J, Montecucco C, et al. Foreword. Toxicon. 2009;54(5):549. DOI: 10.1016/j.toxicon.2009.02.004.

0     

Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord. 2009;24(12):1763-72. PMID: 19562761.

3

Deng H, Zhu SH, Le WD, Yang HR, Lv HW, Xu HB, et al. Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand. 2009;120(6):442-4. PMID: 19922584.

47

Ferrara J, Jankovic J. Acquired hepatocerebral degeneration. J Neurol. 2009;256(3):320-32. PMID: 19224314.

7

Ferrara J, Jankovic J. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009;11(5):293-307. PMID: 19725596.

21

Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285(1-2):195-7. PMID: 19631949.

0     

Frank S, Huntington Study Group/TETRA-HD Investigators. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol. 2009;9:62. PMID: 20021666.

0     

Freeman RD, Zinner SH, Muller-Vahl KR, Fast DK, Burd LJ, Kano Y, et al. Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009;51(3):218-27. PMID: 19183216.

12

Guo Y, Jankovic J, Zhu S, Le W, Song Z, Xie W, et al. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009;454(3):209-11. PMID: 19429085.

10

Gupta A, Jankovic J. Spinocerebellar ataxia 8: variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009;15(9):621-626. PMID: 19559641.

85

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009;24(4):564-73. PMID: 19086083.

56

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, et al. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009;24(4):541-50. PMID: 19058133.

4

Jankovic J, Albanese A, Hallett M. Unique properties of botulinum toxins. Toxicon. 2009;54(5):675. PMID: 19470348.

39

Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009;24(3):407-13. PMID: 19053054.

20

Jankovic J. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009;284(1-2):177-8. PMID: 19361809.

13

Jankovic J. Clinical efficacy and tolerability of Xeomin® in the treatment of blepharospasm. Eur J Neurol. 2009;16(Suppl 2):14-8. PMID: 20002742.

48

Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009;54(5):614-23. PMID: 19073203.

0     

Jankovic J. Movement disorders. Preface. Neurol Clin. 2009;27(3):ix-x. PMID: 19555822.

40

Jankovic J. Peripherally induced movement disorders. Neurol Clin. 2009;27(3):821-32, vii. PMID: 19555833.

111

Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8(9):844-56. PMID: 19679276.

13

Jimenez-Shahed J. Tourette syndrome. Neurol Clin. 2009;27(3):737-55, vi. PMID: 19555829.

0     

Kloppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, et al. Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology. 2009;72(5):426-31. PMID: 19188573.

14

Kuo SH, Vullaganti M, Jimenez-Shahed J, Kwan JY. Camptocormia as a presentation of generalized inflammatory myopathy. Muscle Nerve. 2009;40(6):1059-63. PMID: 19750541.

0     

Latourelle JC, Pankratz N, Dumitriu A, Wilk JB, Goldwurm S, Pezzoli G, et al. Genomewide association study for onset age in Parkinson disease. BMC Med Genet. 2009;10:98. PMID: 19772629.

54

Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009;15(1):28-35. PMID: 19008336.

0     

Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, et al. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009;73(5):385-92. PMID: 19652143.

0     

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, et al. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Mov Disord. 2009;24(16):2370-8. PMID: 19908310.

15

Mata IF, Hutter CM, Gonzalez-Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C, et al. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009;10(4):347-53. PMID: 19308469.

31

 

Mostile G, Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S224-S232. PMID: 20082997.

0     

Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009;72(4):310-6. PMID: 18987351.

448

Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009;361(13):1268-78. PMID: 19776408.

114

Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W. Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 2009;164(2):541-51. PMID: 19682553.

0     

Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, et al. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology. 2009;73(4):279-86. PMID: 19636047.

0     

Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593-605. PMID: 18985386.

0     

Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol. 2009;66(5):563-70. PMID: 19433655.

16

Ravina B, Elm J, Camicioli R, Como PG, Marsh L, Jankovic J, et al. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009;24(9):1306-11. PMID: 19412939.

0     

Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, et al. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009;24(14):2081-90. PMID: 19691116.

17

Sitburana O, Wu LJ, Sheffield JK, Davidson A, Jankovic J. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009;15(10):758-61. PMID: 19505838.

11

Strutt AM, Lai EC, Jankovic J, Atassi F, Soety EM, Levin HS, et al. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009;71(5):551-8. PMID: 18514283.

50

Tagliati M, Jankovic J, Pagan F, Susatia F, Isaias IU, Okun MS. Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage. 2009;47 Suppl 2:T53-7. PMID: 19376247.

101

Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, et al. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009;66(9):1106-13. PMID: 19752299.

10

Wijemanne S, Jankovic J. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009;24(4):583-9. PMID: 19097182.

42

York MK, Wilde EA, Simpson R, Jankovic J. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009;287(1-2):159-71. PMID: 19767016.

70

Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5(2):181-97. PMID: 18394562.

3

Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? Postgrad Med J. 2008;84(992):313-7. PMID: 18644922.

23

Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008;45(15):3878-88. PMID: 18676021.

1

Atassi MZ, Jankovic J, Dolimbek BZ. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;71(13):1040; author reply 1040-1. PMID: 18809844.

3

Azher SN, Jankovic J. Clinical aspects of progressive supranuclear palsy. Handb Clin Neurol. 2008;89:461-73. PMID: 18631769.

86

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353-60. PMID: 18546321.

11

Deng H, Le W, Shahed J, Xie W, Jankovic J. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008;430(1):18-22. PMID: 18068301.

5

Deng H, Le WD, Jankovic J. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008;448(2):180-3. PMID: 18952144.

4

Dulay MF, Strutt AM, Levin HS, Jankovic J, Lai EC, Grossman RG, et al. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008;20(3):357-63. PMID: 18806240.

5

Erer S, Jankovic J. Adult onset tics after peripheral injury. Parkinsonism Relat Disord. 2008;14(1):75-6. PMID: 17292653.

40

Ferrara J, Jankovic J. Psychogenic movement disorders in children. Mov Disord. 2008;23(13):1875-81. PMID: 18709677.

38

Frank S, Ondo W, Fahn S, Hunter C, Oakes D, Plumb S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31(3):127-33. PMID: 18520979.

708

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70. PMID: 19025984.

77

Hallett M, Evinger C, Jankovic J, Stacy M, BEBRF International Workshop. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008;71(16):1275-82. PMID: 18852443.

0     

Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65(12):1582-9. PMID: 19064745.

0     

Jankovic J, Aguilar LG. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat. 2008;4(4):743-57. PMID: 19043519.

40

Jankovic J, Ashoori A. Movement disorders in musicians. Mov Disord. 2008;23(14):1957-65. PMID: 18785647.

17

Jankovic J. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008;63(3):267-9. PMID: 18383071.

5

Jankovic J. Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008;7(1):9-11. PMID: 18093549.

1129

Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-76. PMID: 18344392.

54

Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008;48(3):379-84. PMID: 18223146.

48

Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115(4):585-591. PMID: 17558461.

0     

Kenney C, Jankovic J. Reply: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2008;23(12):1793. PMID: 18709673.

18

Kenney C, Kuo SH, Jimenez-Shahed J. Tourette's syndrome. Am Fam Physician. 2008;77(5):651-8. PMID: 18350763.

4

Kuo SH, Jankovic J. Tardive gait. Clin Neurol Neurosurg. 2008;110(2):198-201. PMID: 17997030.

44

Kuo SH, Kenney C, Jankovic J. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008;23(4):616-9. PMID: 18181207.

57

Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, et al. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008;273(1-2):29-33. PMID: 18684475.

6

Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008;26 Suppl 1:43-53. PMID: 18603167.

105

Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23(15):2194-201. PMID: 18932271.

0     

Oster E, Dorsey ER, Bausch J, Shinaman A, Kayson E, Oakes D, et al. Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A. 2008;146A(16):2070-7. PMID: 18627059.

50

Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008;7(2):720-30. PMID: 18186601.

253

Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008;131(Pt 8):1969-78. PMID: 18187492.

138

Pan T, Kondo S, Zhu W, Xie W, Jankovic J, Le W. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008;32(1):16-25. PMID: 18640276.

11

Pan T, Zhu W, Zhao H, Deng H, Xie W, Jankovic J, et al. Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008;1222:222-9. PMID: 18579122.

0     

Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, et al. Clinical correlates of depressive symptoms in familial Parkinson's disease. Mov Disord. 2008;23(15):2216-23. PMID: 18785635.

0     

Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-80. PMID: 18096682.

0     

Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, et al. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008;71(7):481-5. PMID: 18695158.

0     

Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23. PMID: 18413464.

245

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-706. PMID: 18458230.

19

Sitburana O, Jankovic J. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008;266(1-2):31-3. PMID: 17888455.

0     

Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233-40. PMID: 18519872.

0     

Stamey W, Davidson A, Jankovic J. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008;14(4):253-4. PMID: 18766134.

44

Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008;14(2):89-99. PMID: 18332838.

20

Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008;14(1):77-80. PMID: 17433753.

23

Wu LJ, Sitburana O, Davidson A, Jankovic J. Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008;23(16):2307-11. PMID: 18972544.

71

York MK, Dulay M, Macias A, Levin HS, Grossman R, Simpson R, et al. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008;79(7):789-95. PMID: 17965146.

160

Zhang J, Sokal I, Peskind ER, Quinn JF, Jankovic J, Kenney C, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526-9. PMID: 18343778.

45

Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 2008;105(5):1970-8. PMID: 18399960.

9

Adair JC, Cooke N, Jankovic J. Alexia without agraphia in Creutzfeldt-Jakob disease. J Neurol Sci. 2007;263(1-2):208-10. PMID: 17628601.

22

Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8. PMID: 18267265.

9

Ashoori A, Jankovic J. Mozart's movements and behaviour: a case of Tourette's syndrome? J Neurol Neurosurg Psychiatry. 2007;78(11):1171-5. PMID: 17940168.

4

Atassi MZ, Dolimbek BZ, Deitiker P, Jankovic J, Aoki KR. A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007;20(1):15-21. PMID: 16981247.

61

Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord. 2007;22(12):1743-50. PMID: 17566119.

10

Deng H, Le W, Huang M, Xie W, Pan T, Jankovic J. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007;419(2):104-7. PMID: 17482357.

106

Deng H, Le W, Jankovic J. Genetics of essential tremor. Brain. 2007;130(Pt 6):1456-64. PMID: 17353225.

19

Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007;64(3):421-4. PMID: 17353387.

8

Diamond A, Kenney C, Almaguer M, Jankovic J. Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. J Neurosurg. 2007;107(5):1036-8. PMID: 17977278.

17

Diamond A, Shahed J, Jankovic J. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007;260(1-2):199-203. PMID: 17561121.

49

Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44(5):1029-41. PMID: 16647121.

2

Erer S, Jankovic J. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007;109(9):784-5. PMID: 17618046.

110

Freeman RD, Tourette Syndrome International Database Consortium. Tic disorders and ADHD: Answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry. 2007;16(Suppl 1):15-23. PMID: 17665279.

0     

Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord. 2007;22(2):179-86. PMID: 17094088.

297

Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007;22(1):41-7. PMID: 17115387.

31

Hauser RA, Salin L, Juhel N, Konyago VL, NS 2330 Monotherapy PD Study Group. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007;22(3):359-65. PMID: 17149725.

71

Inzelberg R, Jankovic J. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007;69(15):1542-50. PMID: 17699801.

53

Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007;22(1):55-61. PMID: 17115391.

10

Jankovic J, Deng H. Candidate locus for chorea and tic disorders at 15q? Pediatr Neurol. 2007;37(1):70-3. PMID: 17628228.

99

Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007;21(8):677-92. PMID: 17630819.

42

Jankovic J, Tsui J, Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007;13(7):411-6. PMID: 17442609.

83

Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676-82. PMID: 17502466.

0     

Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, et al. Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain. 2007;130(Pt 7):1732-44. PMID: 17584778.

30

Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007;263(1-2):94-9. PMID: 17604055.

33

Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22(1):10-3. PMID: 17078062.

89

Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22(2):193-7. PMID: 17133512.

10

Kenney C, Jankovic J. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007;8(9):1329-35. PMID: 17563266.

49

Kenney C, Powell S, Jankovic J. Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007;22(1):127-30. PMID: 17115386.

104

Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, et al. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106(4):621-5. PMID: 17432713.

0     

 

Kenney CJ, Hunter CB, Mejia NI, Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Pediatr Neurol. 2007;5(1):9-13.

26

Langbehn DR, Paulsen JS, Huntington Study Group. Predictors of diagnosis in Huntington disease. Neurology. 2007;68(20):1710-7. PMID: 17502553.

43

LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30(5):256-65. PMID: 17909303.

0     

LeWitt PA, Lyons KE, Pahwa R, SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262-7. PMID: 17438216.

41

May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007;22(16):2371-7. PMID: 17914727.

0     

Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, et al. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology. 2007;69(18):1737-44. PMID: 17804834.

4

Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, et al. R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation. Mov Disord. 2007;22(2):254-7. PMID: 17149721.

141

NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20-8. PMID: 17200487.

38

Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord. 2007;13(7):453-4. PMID: 17046312.

16

Ozelius LJ, Foroud T, May S, Senthil G, Sandroni P, Low PA, et al. G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007;22(4):546-9. PMID: 17230458.

0     

Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69(15):1480-90. PMID: 17881719.

7

Poysky J, Jimenez-Shahed J. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2007;22(9):1366-7; author reply 1367-8. PMID: 17469199.

133

Ravina B, Camicioli R, Como PG, Marsh L, Jankovic J, Weintraub D, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342-7. PMID: 17581943.

49

Roessner V, Becker A, Banaschewski T, Freeman RD, Rothenberger A, Tourette Syndrome International Database Consortium. Developmental psychopathology of children and adolescents with Tourette syndrome--impact of ADHD. Eur Child Adolesc Psychiatry. 2007;16 Suppl 1:24-35. PMID: 17665280.

105

Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007;13(2):67-76. PMID: 16887374.

125

Shahed J, Poysky J, Kenney C, Simpson R, Jankovic J. GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007;68(2):159-60. PMID: 17210901.

37

Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007;7(6):637-47. PMID: 17563247.

17

Stamey W, Jankovic J. The other Babinski sign in hemifacial spasm. Neurology. 2007;69(4):402-4. PMID: 17646635.

19

Tan EK, Lee J, Hunter C, Shinawi L, Fook-Chong S, Jankovic J. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007;252(2):113-20. PMID: 17174340.

167

Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272-6. PMID: 17202432.

15

Wijemanne S, Jankovic J. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007;69(16):1585-94. PMID: 17938368.

12

York MK, Lai EC, Jankovic J, Macias A, Atassi F, Levin HS, et al. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007;149(9):857-66; discussion 866. PMID: 17624489.

84

Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb J. 2007;21(14):3835-44. PMID: 17690154.

245

Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293-348. PMID: 16914840.

77

Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006;21(11):1856-63. PMID: 16941460.

46

Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord. 2006;21(5):616-23. PMID: 16450340.

16

Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006;21(9):1500-2. PMID: 16758485.

89

Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, Kordower JH. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006;494(3):495-514. PMID: 16320253.

0     

 

Clarke A, Jankovic J. Selegiline orally disintegrating tablet in the treatment of Parkinson's disease. Therapy. 2006;3(3):349-56. DOI: 10.2217/14750708.3.3.349.

31

Collins A, Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006;67(6):1083-5. PMID: 17000985.

17

Deng H, Le W, Davidson AL, Xie W, Jankovic J. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006;407(2):97-100. PMID: 16939701.

32

Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006;251(1-2):102-6. PMID: 17097110.

16

Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006;63(2):273-7. PMID: 16476817.

50

Deng H, Le WD, Xie WJ, Jankovic J. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006;114(6):400-2. PMID: 17083340.

12

Deng H, Xie W, Guo Y, Le W, Jankovic J. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006;21(5):728-9. PMID: 16552756.

31

Deng H, Xie WJ, Le WD, Huang MS, Jankovic J. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006;401(1-2):16-9. PMID: 16530959.

12

Diamond A, Jankovic J. Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006;5(2):169. PMID: 17173593.

27

Diamond A, Jankovic J. Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006;6(8):1181-97. PMID: 16893346.

17

Diamond A, Kenney C, Jankovic J. Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006;21(8):1273-5. PMID: 16703589.

51

Diamond A, Shahed J, Azher S, Dat-Vuong K, Jankovic J. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006;21(5):692-5. PMID: 16342255.

0     

Elble RJ, Pullman SL, Matsumoto JY, Raethjen J, Deuschl G, Tintner R, et al. Tremor amplitude is logarithmically related to 4- and 5-point tremor rating scales. Brain. 2006;129(Pt 10):2660-6. PMID: 16891320.

26

Elble RJ, Tremor Research Group. Report from a U.S. conference on essential tremor. Mov Disord. 2006;21(12):2052-61. PMID: 17078051.

17

Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L. HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006;21(3):306-9. PMID: 16211613.

0     

Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol. 2006;63(7):991-6. PMID: 16831969.

0     

Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-72. PMID: 16476934.

55

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006;67(12):2233-5. PMID: 17190952.

16

Jankovic J, Kwak C, Frankoff R. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006;18(1):86-95. PMID: 16525075.

15

Jankovic J, Mejia NI. Tics associated with other disorders. Adv Neurol. 2006;99:61-8. PMID: 16536352.

38

Jankovic J, Vuong KD, Thomas M. Psychogenic tremor: long-term outcome. CNS Spectr. 2006;11(7):501-8. PMID: 16816790.

35

Jankovic J. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006;73(4):682-9. PMID: 16878274.

46

Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006;9(2-3):145-8. PMID: 16785112.

0     

 

Jankovic J. Negotiating movement disorders. CNS Spectr. 2006;11(7):500.

162

Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5(10):864-72. PMID: 16987733.

98

Jeanneteau F, Funalot B, Jankovic J, Deng H, Lagarde JP, Lucotte G, et al. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006;103(28):10753-8. PMID: 16809426.

26

Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259-64. PMID: 16960470.

84

Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6(1):7-17. PMID: 16466307.

144

Mink JW, Walkup J, Frey KA, Como P, Cath D, Delong MR, et al. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006;21(11):1831-8. PMID: 16991144.

90

Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, et al. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006;66(5):672-7. PMID: 16436648.

11

Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006;21(8):1252-4. PMID: 16673406.

160

Pahwa R, Lyons KE, Wilkinson SB, Simpson RK, Jr, Ondo WG, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006;104(4):506-12. PMID: 16619653.

21

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, et al. Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. Mov Disord. 2006;21(12):2257-60. PMID: 17078063.

0     

Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Wojcieszek J, et al. Mutations in DJ-1 are rare in familial Parkinson disease. Neurosci Lett. 2006;408(3):209-13. PMID: 16997464.

83

Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138-48. PMID: 16511548.

0     

Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, et al. Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol. 2006;63(6):883-90. PMID: 16769871.

160

Scahill L, Erenberg G, Berlin CM, Jr, Budman C, Coffey BJ, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006;3(2):192-206. PMID: 16554257.

70

Shatunov A, Sambuughin N, Jankovic J, Elble R, Lee HS, Singleton AB, et al. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006;129(Pt 9):2318-31. PMID: 16702189.

46

Tan EK, Jankovic J. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol. 2006;63(9):1232-7. PMID: 16966499.

43

Thomas M, Vuong KD, Jankovic J. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006;12(6):382-7. PMID: 16737838.

36

Wu LJ, Jankovic J. Runner's dystonia. J Neurol Sci. 2006;251(1-2):73-6. PMID: 17097111.

58

Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005;4(7):423-31. PMID: 15963445.

177

Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005;65(3):355-9. PMID: 16087897.

122

Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-9. PMID: 16275831.

101

Deng H, Jankovic J, Guo Y, Xie W, Le W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 2005;337(4):1133-8. PMID: 16226715.

61

Deng H, Le W, Guo Y, Hunter CB, Xie W, Jankovic J. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005;57(6):933-4. PMID: 15929036.

30

Deng H, Le WD, Guo Y, Huang MS, Xie WJ, Jankovic J. Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005;65(4):651-2. PMID: 16116142.

10

Deng H, Le WD, Xie WJ, Pan TH, Zhang X, Jankovic J. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005;382(3):297-9. PMID: 15925106.

12

Deng H, Le WD, Zhang X, Pan TH, Jankovic J. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005;111(6):351-2. PMID: 15876334.

80

Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005;76(9):1188-93. PMID: 16107348.

47

Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Tan EK, Rooney JP. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;64(3):417-21. PMID: 15699368.

31

Hogarth P, Kayson E, Kieburtz K, Marder K, Oakes D, Rosas D, et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord. 2005;20(3):293-7. PMID: 15584032.

19

Imam SZ, Jankovic J, Ali SF, Skinner JT, Xie W, Conneely OM, et al. Nitric oxide mediates increased susceptibility to dopaminergic damage in Nurr1 heterozygous mice. Faseb J. 2005;19(11):1441-50. PMID: 16126911.

138

Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005;77(1-2):128-38. PMID: 16243425.

20

Jankovic J, Noebels JL. Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005;115(3):584-6. PMID: 15765140.

7

Jankovic J. Dystonia and other deformities in Parkinson's disease. J Neurol Sci. 2005;239(1):1-3. PMID: 16199057.

240

Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005;20 Suppl 11:S11-6. PMID: 15822109.

40

Jankovic J. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005;62(3):351-2. PMID: 15767498.

106

Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005;64(12):2021-8. PMID: 15985567.

80

Jiang C, Wan X, He Y, Pan T, Jankovic J, Le W. Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol. 2005;191(1):154-62. PMID: 15589522.

0     

Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D, SELECT-TC Study Group. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm (Vienna). 2005;112(2):221-30. PMID: 15503197.

19

Mejia NI, Jankovic J. Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005;20(1):86-9. PMID: 15390048.

30

Mejia NI, Jankovic J. Secondary tics and tourettism. Rev Bras Psiquiatr. 2005;27(1):11-7. PMID: 15867978.

105

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592-7. PMID: 15645481.

50

Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005;20 Suppl 11:S3-10. PMID: 15822111.

157

Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005;76(12):1636-9. PMID: 16291885.

53

Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005;579(30):6716-20. PMID: 16313906.

35

Pan T, Xie W, Jankovic J, Le W. Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005;377(2):106-9. PMID: 15740846.

0     

Paulsen JS, Hoth KF, Nehl C, Stierman L, Huntington Study Group. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry. 2005;162(4):725-31. PMID: 15800145.

7

Ross S, Jankovic J. Palatal myoclonus: an unusual presentation. Mov Disord. 2005;20(9):1200-3. PMID: 15929094.

15

Shatunov A, Jankovic J, Elble R, Sambuughin N, Singleton A, Hallett M, et al. A variant in the HS1-BP3 gene is associated with familial essential tremor. Neurology. 2005;65(12):1995; author reply 1995. PMID: 16380635.

28

Silay YS, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005;10(2):365-80. PMID: 15934872.

50

Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65(5):765-7. PMID: 16157918.

36

Tintner R, Manian P, Gauthier P, Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005;62(8):1290-5. PMID: 16087771.

117

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783-91. PMID: 15736159.

14

Wan XH, Vuong KD, Jankovic J. Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005;20(1):44-7. PMID: 15844312.

0     

 

Bigalke H, Dressler D, Jankovic J. Basic and therapeutic aspects of neurotoxins. Mov Disord. 2004;19(Suppl 8):S1.

16

Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004;63(6):1096-8. PMID: 15452308.

171

Bruno MK, Hallett M, Gwinn-Hardy K, Sorensen B, Considine E, Tucker S, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology. 2004;63(12):2280-7. PMID: 15623687.

14

de Carvalho Aguiar P, Fazzari M, Jankovic J, Ozelius LJ. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004;19(10):1237-8. PMID: 15368614.

44

Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. Jama. 2004;292(14):1685-6. PMID: 15479932.

19

Higgins JJ, Lombardi RQ, Tan EK, Jankovic J, Pucilowska J, Rooney JP. Haplotype analysis at the ETM2 locus in a Singaporean sample with familial essential tremor. Clin Genet. 2004;66(4):353-7. PMID: 15355439.

0     

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044-53. PMID: 15262734.

25

Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27(5):234-44. PMID: 15602105.

29

Jankovic J, Madisetty J, Vuong KD. Essential tremor among children. Pediatrics. 2004;114(5):1203-5. PMID: 15520096.

219

Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75(7):951-7. PMID: 15201348.

31

Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004;94:275-86. PMID: 14509685.

1

Jankovic J. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004;63(8):1541-2; author reply 1541-2. PMID: 15505193.

81

Jankovic J. Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004;19 Suppl 8:S109-15. PMID: 15027062.

5

Jiang C, Wan X, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, et al. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004;27(2):63-73. PMID: 15252266.

8

Lassinger BK, Kwak C, Walford RL, Jankovic J. Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004;19(4):465-9. PMID: 15077246.

91

Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, et al. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004;62(11):2005-9. PMID: 15184605.

152

Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-90. PMID: 15265242.

29

Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, et al. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. Mov Disord. 2004;19(6):649-55. PMID: 15197702.

0     

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61(10):1563-8. PMID: 15477510.

136

Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62(1):37-40. PMID: 14718694.

18

Ondo WG, Jimenez JE, Vuong KD, Jankovic J. An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004;27(6):274-7. PMID: 15613931.

0     

Pan T, Le W, Jankovic J. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004;62(2):343; author reply 343-4. PMID: 14750218.

0     

Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology. 2004;62(9):1616-8. PMID: 15136695.

0     

Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004;351(24):2498-508. PMID: 15590952.

7

Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004;94:29-36. PMID: 14509651.

146

Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004;219(1-2):63-9. PMID: 15050439.

76

Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004;19(6):692-5. PMID: 15197710.

94

Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004;19(1):36-42. PMID: 14743358.

55

Thomas M, Jankovic J, Suteerawattananon M, Wankadia S, Caroline KS, Vuong KD, et al. Clinical Gait and Balance Scale (GABS): validation and utilization. J Neurol Sci. 2004;217(1):89-99. PMID: 14675615.

79

Thomas M, Jankovic J. Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004;17(4):437-42. PMID: 15247539.

60

Thomas M, Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs. 2004;18(7):437-52. PMID: 15139799.

152

Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology. 2003;60(5):796-801. PMID: 12629236.

0     

Frampton JE, Easthope SE. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines. Am J Clin Dermatol. 2003;4(10):709-25. PMID: 14507232.

14

Handforth A, Ondo WG, Tatter S, Mathern GW, Simpson RK, Jr, et al. Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial. Neurology. 2003;61(10):1401-5. PMID: 14638963.

94

He Y, Imam SZ, Dong Z, Jankovic J, Ali SF, Appel SH, et al. Role of nitric oxide in rotenone-induced nigro-striatal injury. J Neurochem. 2003;86(6):1338-45. PMID: 12950443.

27

Higgins JJ, Jankovic J, Lombardi RQ, Pucilowska J, Tan EK, Ashizawa T, et al. Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003;4(4):185-9. PMID: 12761658.

12

Hill AN, Jankovic J, Vuong KD, Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003;18(10):1190-2. PMID: 14534926.

22

Hou JG, Jankovic J. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003;206(1):59-64. PMID: 12480086.

214

Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-8. PMID: 12682332.

18

Kuniyoshi SM, Jankovic J. MDMA and Parkinsonism. N Engl J Med. 2003;349(1):96-7. PMID: 12840102.

118

Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003;18(12):1530-3. PMID: 14673893.

36

Kwak C, Vuong KD, Jankovic J. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003;60(11):1595-8. PMID: 14623732.

286

Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003;33(1):85-9. PMID: 12496759.

182

Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12(24):3259-67. PMID: 14570706.

36

Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003;10(1):68-79. PMID: 12785750.

65

Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, et al. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003;26(7):461-81. PMID: 12735785.

0     

Mahant N, McCusker EA, Byth K, Graham S, Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003;61(8):1085-92. PMID: 14581669.

505

Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60(1):69-73. PMID: 12525720.

45

Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003;60(7):975-80. PMID: 12873854.

18

Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord. 2003;18(6):683-5. PMID: 12784272.

42

Ondo WG, Sutton L, Dat Vuong K, Lai D, Jankovic J. Hearing impairment in essential tremor. Neurology. 2003;61(8):1093-7. PMID: 14581670.

53

Pan T, Fei J, Zhou X, Jankovic J, Le W. Effects of green tea polyphenols on dopamine uptake and on MPP+ -induced dopamine neuron injury. Life Sci. 2003;72(9):1073-83. PMID: 12495785.

83

Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003;20(10):711-21. PMID: 12875608.

99

Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12(20):2599-608. PMID: 12925570.

108

Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet. 2003;72(4):1053-7. PMID: 12638082.

0     

Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol. 2003;60(12):1721-8. PMID: 14676046.

0     

Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T, et al. Reliability of reported age at onset for Parkinson's disease. Mov Disord. 2003;18(3):275-9. PMID: 12621630.

3

Rosa AL, Jankovic J, Ashizawa T. Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. Arch Neurol. 2003;60(4):502-3. PMID: 12707062.

9

Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003;114(2):288-94. PMID: 12559236.

57

Sanghera MK, Grossman RG, Kalhorn CG, Hamilton WJ, Ondo WG, Jankovic J. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003;52(6):1358-70; discussion 1370-3. PMID: 12762881.

14

Savant CS, Singhal BS, Jankovic J, Khan M, Virani A. Substantia nigra lesions in viral encephalitis. Mov Disord. 2003;18(2):213-6. PMID: 12539218.

16

Simon DK, Friedman J, Breakefield XO, Jankovic J, Brin MF, Provias J, et al. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003;4(4):199-205. PMID: 12756609.

19

Simpkins N, Jankovic J. Neuroprotection in Parkinson disease. Arch Intern Med. 2003;163(14):1650-4. PMID: 12885679.

42

Thomas M, Le WD, Jankovic J. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003;26(1):18-23. PMID: 12567160.

16

Tintner R, Jankovic J. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003;12(11):1803-20. PMID: 14585056.

14

van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, et al. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003;60(7):1189-91. PMID: 12682333.

369

van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003;72(4):804-11. PMID: 12618962.

36

Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003;18(12):1527-30. PMID: 14673892.

55

Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60(6):998-1001. PMID: 12654967.

31

Blakeley J, Jankovic J. Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002;89:401-20. PMID: 11968464.

79

Blakeley J, Jankovic J. Secondary paroxysmal dyskinesias. Mov Disord. 2002;17(4):726-34. PMID: 12210862.

36

Dolimbek BZ, Jankovic J, Atassi MZ. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002;31(3-4):247-62. PMID: 12472183.

26

Jankovic J, Demirkiran M. Classification of paroxysmal dyskinesias and ataxias. Adv Neurol. 2002;89:387-400. PMID: 11968463.

55

Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002;8(4):271-6. PMID: 12039422.

95

Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord. 2002;17(4):638-44. PMID: 12210851.

81

Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58(4 Suppl 1):S19-32. PMID: 11909982.

68

Krauss JK, Jankovic J. Head injury and posttraumatic movement disorders. Neurosurgery. 2002;50(5):927-39; discussion 939-40. PMID: 11950395.

43

Kwak CH, Jankovic J. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002;17(4):821-5. PMID: 12210884.

229

Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70(4):985-93. PMID: 11875758.

42

Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, et al. Linkage stratification and mutation analysis at the Parkin locus identifies mutation positive Parkinson's disease families. J Med Genet. 2002;39(7):489-92. PMID: 12114481.

112

Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17(5):1031-5. PMID: 12360554.

53

Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25(6):300-2. PMID: 12469001.

263

Ondo WG, Vuong KD, Jankovic J. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002;59(3):421-4. PMID: 11890847.

75

Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, et al. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002;17(2):339-45. PMID: 11921121.

130

Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am J Hum Genet. 2002;71(1):124-35. PMID: 12058349.

406

Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-43. PMID: 12470183.

0     

Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. Jama. 2002;287(13):1653-61. PMID: 11926889.

165

Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002;58(3):341-6. PMID: 11839829.

6

Sabbahi M, Etnyre B, Al-Jawayed I, Jankovic J. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002;19(3):245-51. PMID: 12226570.

6

Sabbahi M, Etnyre B, Al-Jawayed IA, Hasson S, Jankovic J. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002;19(1):67-72. PMID: 11896355.

35

Sethi KD, Jankovic J. Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002;17(1):150-3. PMID: 11835453.

0     

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002;51(5):604-12. PMID: 12112107.

31

Tintner R, Jankovic J. Treatment options for Parkinson's disease. Curr Opin Neurol. 2002;15(4):467-76. PMID: 12151845.

76

Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, et al. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002;58(6):881-4. PMID: 11914402.

0     

Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-63. PMID: 11575287.

266

Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology. 2001;56(12):1712-21. PMID: 11425939.

33

Hanna PA, Ratkos L, Ondo WG, Jankovic J. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm. 2001;108(1):63-70. PMID: 11261747.

26

Hou JG, Ondo W, Jankovic J. Intrathecal baclofen for dystonia. Mov Disord. 2001;16(6):1201-2. PMID: 11748766.

0     

 

Jankovic J, Demirkiran M. Paroxysmal dyskinesias: An update. Ann Med Sci. 2001;10(3):92-103.

211

Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001;58(10):1611-5. PMID: 11594919.

3

Jankovic J, Lai EC, Ondo WG, Roberts-Warrior D, Olson SL, Krauss JK, et al. Effects of pallidotomy on gait and balance. Adv Neurol. 2001;87:271-81. PMID: 11347232.

33

Jankovic J, Nutt JG, Sudarsky L. Classification, diagnosis, and etiology of gait disorders. Adv Neurol. 2001;87:119-33. PMID: 11347215.

65

Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001;8(2):109-21. PMID: 11489676.

0     

Jankovic J. Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001;16(1):7-12. PMID: 11215595.

33

Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol. 2001;85:15-29. PMID: 11530424.

38

Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001;24(11):1568-70. PMID: 11745964.

24

Jankovic J. Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001;114(3):227-34. PMID: 11780303.

15

Jankovic J. Parkinson's disease. A half century of progress. Neurology. 2001;57(10 Suppl 3):S1-3. PMID: 11771154.

6

Jankovic J. Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001;58(12):1970-2. PMID: 11735770.

317

Jankovic J. Tourette's syndrome. N Engl J Med. 2001;345(16):1184-92. PMID: 11642235.

53

Krauss JK, Simpson RK, Jr, Ondo WG, Pohle T, Burgunder JM, et al. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001;48(3):535-41; discussion 541-3. PMID: 11270543.

75

Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18(6):389-96. PMID: 11419913.

23

Leckman JF, Cohen DJ, Goetz CG, Jankovic J. Tourette syndrome: pieces of the puzzle. Adv Neurol. 2001;85:369-90. PMID: 11530445.

131

Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics. 2001;3(3):133-43. PMID: 11523564.

144

Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, et al. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. Jama. 2001;286(18):2245-50. PMID: 11710889.

68

Ondo W, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001;58(2):218-22. PMID: 11176959.

15

Ondo W, Dat Vuong K, Almaguer M, Jankovic J, Simpson RK. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001;16(6):1137-42. PMID: 11748749.

250

Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001;57(8):1392-6. PMID: 11673578.

37

Sambuughin N, Nelson TE, Jankovic J, Xin C, Meissner G, Mullakandov M, et al. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord. 2001;11(6-7):530-7. PMID: 11525881.

243

Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. Jama. 2001;286(18):2239-44. PMID: 11710888.

16

Shahed J, Jankovic J. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001;16(1):114-8. PMID: 11215569.

8

Swoboda KJ, Soong BW, McKenna C, Brunt ER, Litt M, Bale JF, et al. Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. Neurology. 2001;57(11 Suppl 4):S42-8. PMID: 11775608.

21

Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001;24(5):247-53. PMID: 11586109.

34

Tan EK, Jankovic J. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001;13(3):380-4. PMID: 11514645.

6

Tan EK, Nagamitsu S, Matsuura T, Khajavi M, Jankovic J, Ondo W, et al. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001;305(1):70-2. PMID: 11356310.

14

Tintner R, Jankovic J. Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001;2(12):1985-94. PMID: 11825330.

13

Tintner R, Jankovic J. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep. 2001;1(4):337-45. PMID: 11898539.

42

Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord. 2001;16(2):252-7. PMID: 11295777.

0     

Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Parkinsonism Relat Disord. 2001;7(2):115-120. PMID: 11248592.

9

Xu P, Liang X, Jankovic J, Le W. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001;58(11):1879-82. PMID: 11708998.

60

Yoshor D, Hamilton WJ, Ondo W, Jankovic J, Grossman RG. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001;48(4):818-24; discussion 824-6. PMID: 11322442.

133

Bain P, Brin M, Deuschl G, Elble R, Jankovic J, Findley L, et al. Criteria for the diagnosis of essential tremor. Neurology. 2000;54(11 Suppl 4):S7. PMID: 10854345.

52

Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000;55(12 Suppl 5):S15-21. PMID: 11188979.

19

Hallett M, Litvan I, Task Force on Surgery for Parkinson's Disease of the American Academy of Neurology Therapeutic and Technology Assessment Committee. Scientific position paper of the Movement Disorder Society evaluation of surgery for Parkinson's disease. Mov Disord. 2000;15(3):436-8. PMID: 10830406.

39

Higgins JJ, Golbe LI, De Biase A, Jankovic J, Factor SA, Adler RL. An extended 5'-tau susceptibility haplotype in progressive supranuclear palsy. Neurology. 2000;55(9):1364-7. PMID: 11087782.

134

Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000;57(3):369-72. PMID: 10714663.

0     

Jankovic J. Atypical and typical cranial dystonia following dental procedures. Mov Disord. 2000;15(2):366. PMID: 10752604.

44

Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000;55(12 Suppl 6):S2-6. PMID: 11188970.

83

Jankovic J. Essential tremor: clinical characteristics. Neurology. 2000;54(11 Suppl 4):S21-5. PMID: 10854348.

23

Jankovic J. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000;23(5):252-61. PMID: 11154092.

2

Kwak C, Jankovic J. Tics in Tourette syndrome and botulinum toxin. J Child Neurol. 2000;15(9):631-4. PMID: 11019798.

108

Kwak CH, Hanna PA, Jankovic J. Botulinum toxin in the treatment of tics. Arch Neurol. 2000;57(8):1190-3. PMID: 10927800.

0     

 

Kwak CH, Jankovic J. Neurobehavioral aspect of Tourette syndrome. Drug Benefit Trends. 2000;12(11):7BH-10BH.

36

Lai EC, Jankovic J, Krauss JK, Ondo WG, Grossman RG. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000;55(8):1218-22. PMID: 11071505.

71

Le WD, Jankovic J, Xie W, Appel SH. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm. 2000;107(10):1165-73. PMID: 11129106.

0     

Litvan I, Dickson DW, Buttner-Ennever JA, Delacourte A, Hutton M, Dubois B, et al. Research goals in progressive supranuclear palsy. Mov Disord. 2000;15(3):446-58. PMID: 10830408.

0     

Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington's disease. Neurology. 2000;54(2):452-8. PMID: 10668713.

92

Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678-82. PMID: 10928578.

28

Ondo W, Warrior D, Overby A, Calmes J, Hendersen N, Olson S, et al. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000;57(10):1464-9. PMID: 11030799.

46

Ondo WG, Ben-Aire L, Jankovic J, Lai E, Contant C, Grossman R. Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000;101(2):79-84. PMID: 10685852.

0     

Ondo WG, Hunter C, Vuong KD, Jankovic J. The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease. Parkinsonism Relat Disord. 2000;6(4):237-240. PMID: 10900399.

709

Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Jama. 2000;284(15):1931-8. PMID: 11035889.

36

Rettig GM, York MK, Lai EC, Jankovic J, Krauss JK, Grossman RG, et al. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000;69(3):326-36. PMID: 10945807.

59

Ringman JM, Jankovic J. Occurrence of tics in Asperger's syndrome and autistic disorder. J Child Neurol. 2000;15(6):394-400. PMID: 10868783.

22

Roberts-Warrior D, Overby A, Jankovic J, Olson S, Lai EC, Krauss JK, et al. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000;123 ( Pt 10):2141-9. PMID: 11004130.

105

Swoboda KJ, Soong B, McKenna C, Brunt ER, Litt M, Bale JF, et al. Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology. 2000;55(2):224-30. PMID: 10908896.

24

Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. Mov Disord. 2000;15(1):171-3. PMID: 10634263.

0     

Tan EK, Jankovic J. Hemifacial spasm and hypertension: how strong is the association? Mov Disord. 2000;15(2):363-5. PMID: 10752602.

62

Tan EK, Jankovic J. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000;68(2):186-90. PMID: 10644785.

96

Tan EK, Jankovic J. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000;131(2):211-6. PMID: 10680389.

191

Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000;55(4):533-8. PMID: 10953187.

18

Tan EK, Matsuura T, Nagamitsu S, Khajavi M, Jankovic J, Ashizawa T. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000;54(5):1195-8. PMID: 10720300.

16

Uc EY, Wenger DA, Jankovic J. Niemann-Pick disease type C: two cases and an update. Mov Disord. 2000;15(6):1199-203. PMID: 11104205.

25

Vanek ZF, Jankovic J. Dystonia in corticobasal degeneration. Adv Neurol. 2000;82:61-7. PMID: 10624471.

75

Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett. 2000;281(2-3):167-70. PMID: 10704769.

277

Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-8. PMID: 10534247.

70

Chokroverty S, Jankovic J. Restless legs syndrome: a disease in search of identity. Neurology. 1999;52(5):907-10. PMID: 10102404.

0     

Gelb DJ, Oliver E, Gilman S, NINDS Advisory Council. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33-9. PMID: 9923759.

0     

Hallett M, Litvan I, Task Force on Surgery for Parkinson's Disease. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1999;53(9):1910-21. PMID: 10599758.

50

Hanna PA, Janjua FN, Contant CF, Jankovic J. Bilineal transmission in Tourette syndrome. Neurology. 1999;53(4):813-8. PMID: 10489047.

44

Hanna PA, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999;56(1):90-4. PMID: 9923766.

60

Hanna PA, Jankovic J, Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999;66(5):612-6. PMID: 10209172.

34

Jankovic J, Ben-Arie L, Schwartz K, Chen K, Khan M, Lai EC, et al. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999;14(1):57-62. PMID: 9918345.

18

Jankovic J, Lai E, Ben-Arie L, Krauss JK, Grossman R. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999;167(1):62-7. PMID: 10500264.

12

Jankovic J, Lai EC, Krauss J, Grossman R. Surgical treatment of levodopa-induced dyskinesias. Adv Neurol. 1999;80:603-9. PMID: 10410777.

121

Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999;67(5):646-50. PMID: 10519872.

0     

Jankovic J. New and emerging therapies for Parkinson disease. Arch Neurol. 1999;56(7):785-90. PMID: 10404979.

137

Le W, Conneely OM, He Y, Jankovic J, Appel SH. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999;73(5):2218-21. PMID: 10537083.

102

Le W, Conneely OM, Zou L, He Y, Saucedo-Cardenas O, Jankovic J, et al. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999;159(2):451-8. PMID: 10506516.

37

Le WD, Rowe DB, Jankovic J, Xie W, Appel SH. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999;56(2):194-200. PMID: 10025424.

77

Litvan I, Grimes DA, Lang AE, Jankovic J, McKee A, Verny M, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999;246 Suppl 2:II1-5. PMID: 10525996.

14

Mathew SJ, Yudofsky SC, McCullough LB, Teasdale TA, Jankovic J. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999;11(2):259-67. PMID: 10333998.

0     

Miller CS, Gammage RB, Jankovic JT. Exacerbation of chemical sensitivity: a case study. Toxicol Ind Health. 1999;15(3-4):398-402. PMID: 10416291.

26

Ondo W, Hunter C, Almaguer M, Gancher S, Jankovic J. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999;22(1):1-4. PMID: 10047926.

30

Ondo W, Hunter C, Almaguer M, Jankovic J. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999;14(4):664-8. PMID: 10435505.

85

Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279-81. PMID: 10450276.

24

Scott WK, Yamaoka LH, Stajich JM, Scott BL, Vance JM, Roses AD, et al. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999;2(3):191-2. PMID: 10541595.

34

Stanley RK, Protas EJ, Jankovic J. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999;31(6):761-6. PMID: 10378900.

59

Tan EK, Jankovic J. Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999;14(2):345-9. PMID: 10091632.

109

Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999;53(9):2102-7. PMID: 10599789.

0     

Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. Jama. 1999;281(4):341-6. PMID: 9929087.

38

Watts MW, Tan EK, Jankovic J. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999;17(3):196-201. PMID: 10650407.

175

Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999;56(1):98-102. PMID: 9923767.

97

Zou L, Jankovic J, Rowe DB, Xie W, Appel SH, Le W. Neuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicity. Life Sci. 1999;64(15):1275-85. PMID: 10227583.

17

Desaloms JM, Krauss JK, Lai EC, Jankovic J, Grossman RG. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998;89(2):194-9. PMID: 9688112.

1049

Deuschl G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;13 Suppl 3:2-23. PMID: 9827589.

81

Hanna PA, Jankovic J. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998;50(6):1624-9. PMID: 9633703.

84

Higgins JJ, Loveless JM, Jankovic J, Patel PI. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord. 1998;13(6):972-7. PMID: 9827627.

12

Jankovic J, Sekula S. Dermatological manifestations of Tourette syndrome and obsessive-compulsive disorder. Arch Dermatol. 1998;134(1):113-4. PMID: 9449929.

41

Jankovic J. Medical therapy and botulinum toxin in dystonia. Adv Neurol. 1998;78:169-83. PMID: 9750914.

18

Jankovic J. Re-emergence of surgery for dystonia. J Neurol Neurosurg Psychiatry. 1998;65(4):434. PMID: 9771761.

40

Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A, et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm. 1998;105(2-3):217-27. PMID: 9660099.

230

Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55(7):969-78. PMID: 9678315.

0     

Litvan II, Jankovic J, Goetz CG, Wenning GK, Sastry N, Jellinger K, et al. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study. Eur J Neurol. 1998;5(5):451-7. PMID: 10210873.

159

Ondo W, Jankovic J, Schwartz K, Almaguer M, Simpson RK. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998;51(4):1063-9. PMID: 9781530.

141

Ondo WG, Desaloms JM, Jankovic J, Grossman RG. Pallidotomy for generalized dystonia. Mov Disord. 1998;13(4):693-8. PMID: 9686777.

64

Ondo WG, Jankovic J, Lai EC, Sankhla C, Khan M, Ben-Arie L, et al. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998;50(1):266-70. PMID: 9443490.

0     

Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol. 1998;43(3):318-25. PMID: 9506548.

17

Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, et al. Decreased [18F]spiperone binding in putamen in dystonia. Adv Neurol. 1998;78:161-8. PMID: 9750913.

65

Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998;13(1):150-4. PMID: 9452341.

84

Sankhla C, Lai EC, Jankovic J. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998;65(5):722-8. PMID: 9810945.

8

Scarano VR, Jankovic J. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998;43(2):334-9. PMID: 9544540.

0     

Shoulson I, Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Ann Neurol. 1998;44(3 Suppl 1):S160-6. PMID: 9749589.

205

Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998;21(12):1740-7. PMID: 9843077.

32

Wang WW, Khajavi M, Patel BJ, Beach J, Jankovic J, Ashizawa T. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998;55(12):1521-3. PMID: 9865795.

220

Wenning GK, Litvan I, Jankovic J, Granata R, Mangone CA, McKee A, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998;64(2):184-9. PMID: 9489528.

0     

 

Brin MF, Albany K, Alexander D, Cava T, Chambers HG, Childers MK, et al. Spasticity, etiology, evaluation, management, and the role of botulinum toxin type A. Muscle Nerve. 1997;20(Suppl. 6):S1-S223.

26

Cardoso F, Jankovic J. Dystonia and dyskinesia. Psychiatr Clin North Am. 1997;20(4):821-38. PMID: 9443352.

32

Jankovic J, Beach J, Pandolfo M, Patel PI. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997;54(3):289-94. PMID: 9074398.

196

Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997;48(2):358-62. PMID: 9040721.

103

Jankovic J, Brin MF. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997;6:S129-45. PMID: 9826986.

10

Jankovic J, Hamilton WJ, Grossman RG. Thalamic surgery for movement disorders. Adv Neurol. 1997;74:221-33. PMID: 9348417.

5

Jankovic J, Ruzicka E. [Tics and Tourette's syndrome]. Cas Lek Cesk. 1997;136(13):399-404. PMID: 9333513.

11

Jankovic J, Scott BL, Evans RW. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1997;12(5):818. PMID: 9380077.

0     

 

Jankovic J. Phenomenology and classification of tics. Neurol Clin. 1997;15(2):267-75.

133

Jankovic J. Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997;15(2):267-75. PMID: 9115460.

87

Krauss JK, Desaloms JM, Lai EC, King DE, Jankovic J, Grossman RG. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997;87(3):358-67. PMID: 9285599.

8

Krauss JK, Grossman RG, Jankovic J. Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997;12(1):124-6. PMID: 8990069.

2

Krauss JK, Grossman RG, Lai EC, Schwartz K, Jankovic J. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997;58(4):153-62. PMID: 9487651.

12

Krauss JK, Jankovic J, Lai EC, Rettig GM, Grossman RG. Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997;54(8):1026-9. PMID: 9267978.

5

Krauss JK, Jankovic J. Hemidystonia secondary to carotid artery gunshot injury. Childs Nerv Syst. 1997;13(5):285-8. PMID: 9224919.

20

Krauss JK, Jankovic J. Tics secondary to craniocerebral trauma. Mov Disord. 1997;12(5):776-82. PMID: 9380066.

32

Krauss JK, Seeger W, Jankovic J. Cervical dystonia associated with tumors of the posterior fossa. Mov Disord. 1997;12(3):443-7. PMID: 9159745.

52

Krauss JK, Toups EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997;63(5):642-8. PMID: 9408107.

37

Le W, Jankovic J, Xie W, Kong R, Appel SH. (-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition. Neurosci Lett. 1997;224(3):197-200. PMID: 9131670.

187

Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701-7. PMID: 9305326.

0     

Lieberman A, Ranhosky A, Korts D, Pramipexole Study Group Investigators. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49(1):162-8. PMID: 9222185.

311

Litvan I, Agid Y, Goetz C, Jankovic J, Wenning GK, Brandel JP, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997;48(1):119-25. PMID: 9008506.

62

Litvan I, Agid Y, Sastry N, Jankovic J, Wenning GK, Goetz CG, et al. What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology. 1997;49(1):62-9. PMID: 9222171.

150

Litvan I, Goetz CG, Jankovic J, Wenning GK, Booth V, Bartko JJ, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997;54(8):937-44. PMID: 9267967.

0     

Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA, Midodrine Study Group. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Jama. 1997;277(13):1046-51. PMID: 9091692.

0     

Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol. 1997;42(5):747-55. PMID: 9392574.

151

Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovic J, et al. Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci. 1997;17(2):843-50. PMID: 8987805.

0     

Scott WK, Staijich JM, Yamaoka LH, Speer MC, Vance JM, Roses AD, et al. Genetic complexity and Parkinson's disease. Science. 1997;277(5324):387-8; author reply 389. PMID: 9518366.

8

Alford RL, Ashizawa T, Jankovic J, Caskey CT, Richards CS. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996;66(3):281-6. PMID: 8985488.

10

Ashizawa T, Jankovic J. Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996;11(4):457-9. PMID: 8813235.

688

Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996;46(5):1470. PMID: 8628505.

75

Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19(2):157-64. PMID: 8777769.

42

Demirkiran M, Jankovic J, Lewis RA, Cox DW. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology. 1996;46(4):1040-3. PMID: 8780087.

57

Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology. 1996;46(4):965-8. PMID: 8780073.

0     

Hallett M, Daroff RB, Benign Essential Blepharospasm Research Foundation. Blepharospasm: report of a workshop. Neurology. 1996;46(5):1213-8. PMID: 8628455.

125

Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11(3):250-6. PMID: 8723140.

27

Jankovic J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry. 1996;60(6):704. PMID: 8648354.

58

Krauss JK, Akeyson EW, Giam P, Jankovic J. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996;83(2):420-22. PMID: 8694329.

51

Krauss JK, Jankovic J. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996;11(5):563-6. PMID: 8866498.

17

Krauss JK, Jankovic J. Surgical treatment of Parkinson's disease. Am Fam Physician. 1996;54(5):1621-9. PMID: 8857784.

1310

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1-9. PMID: 8710059.

248

Litvan I, Agid Y, Jankovic J, Goetz C, Brandel JP, Lai EC, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996;46(4):922-30. PMID: 8780065.

54

Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: differentiation from Alzheimer's disease. Neurology. 1996;46(3):720-6. PMID: 8618672.

0     

 

Ondo W, Jankovic J. Essential tremor. Treatment options. CNS Drugs. 1996;6(3):178-91.

264

Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47(6):1435-41. PMID: 8960723.

0     

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39(1):37-45. PMID: 8572664.

0     

Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol. 1996;39(1):29-36. PMID: 8572663.

42

Protas EJ, Stanley RK, Jankovic J, MacNeill B. Cardiovascular and metabolic responses to upper- and lower-extremity exercise in men with idiopathic Parkinson's disease. Phys Ther. 1996;76(1):34-40. PMID: 8545491.

0     

 

Protas EJ, Stanley RK, Jankovic J. Exercise and Parkinson's disease. Crit Rev Phys Rehabil Med. 1996;8(4):253-66.

26

Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord. 1996;11(6):748-51. PMID: 8914109.

48

Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996;11(4):431-3. PMID: 8813224.

112

Scott BL, Jankovic J. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996;46(1):68-74. PMID: 8559423.

100

Cardoso F, Jankovic J, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995;36(3):501-7; discussion 507-8. PMID: 7753350.

10

Cardoso F, Jankovic J. Clinical use of botulinum neurotoxins. Curr Top Microbiol Immunol. 1995;195:123-41. PMID: 8542751.

51

Cardoso F, Jankovic J. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995;52(3):263-70. PMID: 7872879.

29

Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardoso F. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995;7(4):471-5. PMID: 8555750.

330

Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995;38(4):571-9. PMID: 7574453.

49

Jankovic J, Ashizawa T. Tourettism associated with Huntington's disease. Mov Disord. 1995;10(1):103-5. PMID: 7885343.

12

Jankovic J, Beach J, Ashizawa T. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995;32(7):516-8. PMID: 7562962.

67

Jankovic J, Beach J, Schwartz K, Contant C. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995;45(4):645-8. PMID: 7723949.

187

Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995;37(4):680-6; discussion 686-7. PMID: 8559296.

258

Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45(9):1743-6. PMID: 7675238.

21

Jankovic J. Apraxia of lid opening. Mov Disord. 1995;10(5):686-7. PMID: 8552131.

9

Jankovic J. International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord. 1995;10(5):533-40. PMID: 8552102.

87

Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995;18(3):197-214. PMID: 8635179.

41

McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol. 1995;52(6):565-70. PMID: 7763203.

0     

Parkinson Study Group. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol. 1995;52(3):237-45. PMID: 7872875.

42

Pezzoli G, Martignoni E, Pacchetti C, Angeleri V, Lamberti P, Muratorio A, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology. 1995;45(3):S22-7. PMID: 7715793.

15

Shulman LM, Lang AE, Jankovic J, David NJ, Weiner WJ. What is it? Case 1, 1995: Psychosis, dementia, chorea, ataxia, and supranuclear gaze dysfunction. Mov Disord. 1995;10(3):257-62. PMID: 7651440.

48

Ashizawa T, Wong LJ, Richards CS, Caskey CT, Jankovic J. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994;44(6):1137-43. PMID: 8208412.

28

Di Monte DA, Harati Y, Jankovic J, Sandy MS, Jewell SA, Langston JW. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem. 1994;62(4):1631-4. PMID: 8133289.

7

Jankovic J, Shoulson I, Weiner WJ. Early-stage Parkinson's disease: to treat or not to treat. Neurology. 1994;44(3 Suppl 1):S4-7. PMID: 8121578.

69

Jankovic J. Botulinum toxin in movement disorders. Curr Opin Neurol. 1994;7(4):358-66. PMID: 7952246.

74

Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994;9(3):347-9. PMID: 8041378.

193

Jankovic J. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994;44(11):2006-14. PMID: 7969951.

205

Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord. 1994;9(1):40-7. PMID: 8139604.

44

Percy AK, Glaze DG, Schultz RJ, Zoghbi HY, Williamson D, Frost JD, et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35(4):464-70. PMID: 8154874.

25

Piwinski SE, Jankovic J, McElligott MA. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994;34(5):466-71. PMID: 7522240.

38

Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Neurology. 1994;44(12):2401-3. PMID: 7991136.

53

Winikates J, Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:189-201. PMID: 7964687.

11

Wojcieszek J, Lang AE, Jankovic J, Greene P, Deck J. What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. Mov Disord. 1994;9(3):358-66. PMID: 7518892.

25

Cardoso F, Jankovic J. Movement disorders. Neurol Clin. 1993;11(3):625-38. PMID: 8377747.

53

Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord. 1993;8(2):175-8. PMID: 8474485.

38

Cardoso FE, Jankovic J. Hereditary motor-sensory neuropathy and movement disorders. Muscle Nerve. 1993;16(9):904-10. PMID: 8355721.

48

Chacko RC, Hurley RA, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci. 1993;5(2):206-8. PMID: 8508040.

13

Jankovic J, Contant C, Perlmutter J. Essential tremor and PD. Neurology. 1993;43(7):1447-9. PMID: 8327160.

235

Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38-48. PMID: 7687093.

12

Jankovic J, Rajput AH, Golbe LI, Goodman JC. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993;8(4):525-32. PMID: 8232366.

92

Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993;43(4):834-6. PMID: 8469349.

26

Jankovic J, Schwartz KS. Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg Am. 1993;18(5):883-7. PMID: 8228064.

49

Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol. 1993;50(3):286-8. PMID: 8442708.

0     

 

Jankovic J. Natural course and limitations of levodopa therapy. Neurology. 1993;43(2 Suppl 1):S14-7.

0     

 

Jankovic J. Theories on the etiology and pathogenesis of parkinson?s disease. Neurology. 1993;43(2 Suppl 1):S21-S-23.

92

Monday K, Jankovic J. Psychogenic myoclonus. Neurology. 1993;43(2):349-52. PMID: 8437701.

0     

Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Ann Neurol. 1993;33(4):350-6. PMID: 8489205.

0     

Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328(3):176-83. PMID: 8417384.

48

Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993;43(5):937-41. PMID: 8492949.

3

Stacy M, Jankovic J. Childhood dystonia. Pediatr Ann. 1993;22(1):53-8. PMID: 8430034.

18

Stacy M, Jankovic J. Current approaches in the treatment of Parkinson's disease. Annu Rev Med. 1993;44:431-40. PMID: 8476262.

0     

Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol. 1993;50(10):1013-6. PMID: 8215958.

4

Burnett L, Jankovic J. Chorea and ballism. Curr Opin Neurol Neurosurg. 1992;5(3):308-13. PMID: 1535815.

105

Doody RS, Jankovic J. The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992;55(9):806-10. PMID: 1402972.

30

Friedman DI, Jankovic J, McCrary JA, 3rd. Neuro-ophthalmic findings in progressive supranuclear palsy. J Clin Neuroophthalmol. 1992;12(2):104-9. PMID: 1629370.

31

Jankovic J, Wooten M, Van der Linden C, Jansson B. Low body weight in Parkinson's disease. South Med J. 1992;85(4):351-4. PMID: 1566133.

30

Jankovic J. Diagnosis and classification of tics and Tourette syndrome. Adv Neurol. 1992;58:7-14. PMID: 1414646.

11

Lew H, Jordan C, Jerger J, Jankovic J. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992;42(3 Pt 1):594-7. PMID: 1549220.

13

Miller LG, Jankovic J. Persistent dystonia possibly induced by flecainide. Mov Disord. 1992;7(1):62-3. PMID: 1557067.

0     

Shoulson I, Parkinson Study Group. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease. Eur Neurol. 1992;32 Suppl 1:46-53. PMID: 1425820.

69

Stacy M, Jankovic J. Differential diagnosis of Parkinson's disease and the parkinsonism plus syndromes. Neurol Clin. 1992;10(2):341-59. PMID: 1584178.

63

Stacy M, Jankovic J. Tardive tremor. Mov Disord. 1992;7(1):53-7. PMID: 1348352.

56

Blum P, Jankovic J. Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991;6(1):12-20. PMID: 2005917.

49

FitzGerald PM, Jankovic J. Orthostatic tremor: an association with essential tremor. Mov Disord. 1991;6(1):60-4. PMID: 2005923.

92

Goetz CG, Stebbins GT, 3rd, Klawans HL, Koller WC, Grossman RG, et al. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991;41(11):1719-22. PMID: 1944898.

592

Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med. 1991;324(17):1186-94. PMID: 2011163.

244

Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991;41(7):1088-91. PMID: 2067638.

89

Jankovic J, Schwartz K. Botulinum toxin treatment of tremors. Neurology. 1991;41(8):1185-8. PMID: 1866001.

90

Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991;48(12):1253-6. PMID: 1845028.

32

Jankovic J, Stone L. Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991;6(3):248-52. PMID: 1922130.

0     

LeWitt PA, Parkinson Study Group. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP study. Acta Neurol Scand Suppl. 1991;136:79-86. PMID: 1801542.

226

Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology. 1991;41(2 ( Pt 1)):234-8. PMID: 1992367.

93

Narayan RK, Loubser PG, Jankovic J, Donovan WH, Bontke CF. Intrathecal baclofen for intractable axial dystonia. Neurology. 1991;41(7):1141-2. PMID: 2067645.

5

Narayana PA, Slopis JM, Jackson EF, Jankovic J, Butler IJ. Proton magnetic resonance spectroscopic studies of hypertrophied muscle. Effect of botulinum toxin treatment. Invest Radiol. 1991;26(1):58-64. PMID: 2022454.

0     

National Institutes of Health Consensus Development Conference Statement. Clinical use of botulinum toxin. Arch Neurol. 1991;48(12):1294-8. PMID: 1845036.

0     

Parkinson Study Group. DATATOP and clinical neuromythology IX. Neurology. 1991;41(6):771-7. PMID: 1904562.

0     

 

Stacy M, Jankovic J. Tardive dyskinesia. Curr Opin Neurol Neurosurg. 1991;4(3):343-9.

26

Stone LA, Jankovic J. The coexistence of tics and dystonia. Arch Neurol. 1991;48(8):862-5. PMID: 1898264.

29

Taylor LD, Krizman DB, Jankovic J, Hayani A, Steuber PC, Greenberg F, et al. 9p monosomy in a patient with Gilles de la Tourette's syndrome. Neurology. 1991;41(9):1513-5. PMID: 1679912.

24

Carter JB, Patrinely JR, Jankovic J, McCrary JA, 3rd, Boniuk M. Familial hemifacial spasm. Arch Ophthalmol. 1990;108(2):249-50. PMID: 2302111.

40

FitzGerald PM, Jankovic J, Glaze DG, Schultz R, Percy AK. Extrapyramidal involvement in Rett's syndrome. Neurology. 1990;40(2):293-5. PMID: 2073236.

51

FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5(3):195-202. PMID: 2388636.

32

Jankovic J, Friedman DI, Pirozzolo FJ, McCrary JA. Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990;53:293-304. PMID: 2239467.

557

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990;40(10):1529-34. PMID: 2215943.

267

Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990;53(8):633-9. PMID: 2213039.

222

Jankovic J, Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40(2):277-80. PMID: 2300249.

6

Jankovic J. Lower body (vascular) parkinsonism. Arch Neurol. 1990;47(7):728. PMID: 2357151.

0     

Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990;83(5):525-32. PMID: 1971459.

15

Miller LG, Jankovic J. Sulpiride-induced tardive dystonia. Mov Disord. 1990;5(1):83-4. PMID: 1967484.

7

Persing JA, Muir A, Becker DG, Jankovic JJ, Anderson RL, Edlich RF. Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. J Emerg Med. 1990;8(5):571-4. PMID: 2254604.

37

Beall SS, Patten BM, Mallette L, Jankovic J. Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr's syndrome. Ann Neurol. 1989;26(4):569-75. PMID: 2817830.

86

Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord. 1989;4(2):157-75. PMID: 2567492.

191

Dewey RB, Jr, Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989;46(8):862-7. PMID: 2757526.

155

FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989;4(3):249-60. PMID: 2779595.

38

FitzGerald PM, Jankovic J. Tardive oculogyric crises. Neurology. 1989;39(11):1434-7. PMID: 2573005.

59

Jankovic J, Grossman R, Goodman C, Pirozzolo F, Schneider L, Zhu Z, et al. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989;39(9):1227-34. PMID: 2475820.

36

Jankovic J, Schwartz K, Vander Linden C. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989;4(4):303-9. PMID: 2682215.

52

Jankovic J, Shale H. Dystonia in musicians. Semin Neurol. 1989;9(2):131-5. PMID: 2602695.

22

Jankovic J. Essential tremor and Parkinson's disease. Ann Neurol. 1989;25(2):211-2. PMID: 2919875.

34

Jankovic J. Parkinsonism-plus syndromes. Mov Disord. 1989;4 Suppl 1:S95-119. PMID: 2657411.

0     

 

Jankovic J. Tremor, tic and myoclonic disorders. Curr Opin Neurol Neurosurg. 1989;2(3):324-9.

147

Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989;149(11):2486-92. PMID: 2684075.

10

Nath A, Jankovic J. Motor disorders in patients with human immunodeficiency virus infection. Prog AIDS Pathol. 1989;1:159-66. PMID: 2491240.

0     

Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46(10):1052-60. PMID: 2508608.

0     

Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321(20):1364-71. PMID: 2509910.

0     

Shoulson I, Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurol Scand Suppl. 1989;126:171-5. PMID: 2515723.

0     

 

Dure L, Jankovic J. Childhood-onset movement disorders. Curr Opin Neurol Neurosurg. 1988;1(3):347-52.

0     

 

Fahn S, Jankovic J. Extrapyramidal, developmental and inherited CNS disease. Overview. Curr Opin Neurol Neurosurg. 1988;1(3):269-70.

2

Jankovic J, Armstrong D, Low NL, Goetz CG. Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988;3(4):352-61. PMID: 3211183.

0     

Jankovic J, Armstrong D, Low NL, Rapin I. Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. Mov Disord. 1988;3(4):362-9. PMID: 3145418.

87

Jankovic J, Caskey TC, Stout JT, Butler IJ. Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988;23(5):466-9. PMID: 2455472.

26

Jankovic J, Nutt JG. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988;49:117-23. PMID: 3344632.

147

Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38(3):391-4. PMID: 3279337.

186

Jankovic J, Van der Linden C. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988;51(12):1512-9. PMID: 3221219.

29

Jankovic J. Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988;50:583-91. PMID: 3041763.

17

Jankovic J. Botulinum A toxin in the treatment of blepharospasm. Adv Neurol. 1988;49:467-72. PMID: 3278552.

25

Jankovic J. Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988;49:1-13. PMID: 3278534.

58

Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988;49:103-16. PMID: 3278535.

0     

Jankovic J. Hemiparkinsonism and hemiatrophy. Neurology. 1988;38(11):1815-6. PMID: 3185927.

6

Jankovic J. Orofacial and other self-mutilations. Adv Neurol. 1988;49:365-81. PMID: 3278547.

7

Jankovic J. Parkinson's disease: recent advances in therapy. South Med J. 1988;81(8):1021-7. PMID: 3043683.

23

Percy AK, Zoghbi HY, Lewis KR, Jankovic J. Rett syndrome: qualitative and quantitative differentiation from autism. J Child Neurol. 1988;3 Suppl:S65-7. PMID: 3198904.

91

Rosenbaum F, Jankovic J. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988;38(4):522-7. PMID: 3352903.

17

Singh SK, Jankovic J. Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988;3(3):274-80. PMID: 2904122.

78

Dubinsky RM, Jankovic J. Progressive supranuclear palsy and a multi-infarct state. Neurology. 1987;37(4):570-6. PMID: 3561771.

23

Jankovic J, Casabona J. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987;10(6):511-21. PMID: 2892586.

257

Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology. 1987;37(4):616-23. PMID: 3561773.

24

Jankovic J, Orman J. Parallel double-blind study of pergolide in Parkinson's disease. Adv Neurol. 1987;45:551-4. PMID: 3548265.

20

Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord. 1987;2(3):159-63. PMID: 3509774.

65

Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987;14(3 Suppl):541-6. PMID: 2890426.

48

Jankovic J, Svendsen CN, Bird ED. Brain neurotransmitters in dystonia. N Engl J Med. 1987;316(5):278-9. PMID: 2879237.

35

Koller W, O'Hara R, Weiner W, Lang A, Nutt J, Agid Y, et al. Relationship of aging to Parkinson's disease. Adv Neurol. 1987;45:317-21. PMID: 3493630.

15

Kurlan R, Jankovic J, Rubin A, Patten B, Griggs R, Shoulson I. Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? Arch Neurol. 1987;44(10):1057-60. PMID: 3632379.

28

Little JT, Jankovic J. Tardive myoclonus. Mov Disord. 1987;2(4):307-11. PMID: 3504556.

110

Miller RH, Woodson GE, Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia. A preliminary report. Arch Otolaryngol Head Neck Surg. 1987;113(6):603-5. PMID: 3566940.

137

Nath A, Jankovic J, Pettigrew LC. Movement disorders and AIDS. Neurology. 1987;37(1):37-41. PMID: 3796836.

0     

Friedman DI, Jankovic J, Rolak LA. Arteriovenous malformation presenting as hemidystonia. Neurology. 1986;36(12):1590-3. PMID: 3785674.

5

Gospe SM, Jr, Jankovic J. Drug-induced dystonia in neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1986;2(4):236-7. PMID: 3508694.

17

Inbody S, Jankovic J. Hyperkinetic mutism: bilateral ballism and basal ganglia calcification. Neurology. 1986;36(6):825-7. PMID: 3703289.

33

Jankovic J, Fahn S. The phenomenology of tics. Mov Disord. 1986;1(1):17-26. PMID: 3332803.

32

Jankovic J, Newmark M, Peter P. Parkinsonism and acquired hydrocephalus. Mov Disord. 1986;1(1):59-64. PMID: 3504232.

35

Jankovic J, Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology. 1986;36(2):303-4. PMID: 3945407.

141

Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol. 1986;43(10):1025-31. PMID: 3753263.

16

Jankovic J, Reches A. Parkinson's disease in monozygotic twins. Ann Neurol. 1986;19(4):405-8. PMID: 3707096.

55

Jankovic J. Blepharospasm with basal ganglia lesions. Arch Neurol. 1986;43(9):866-8. PMID: 3741202.

4

Jankovic J. Myoglobinuric renal failure in Huntington's chorea. Neurology. 1986;36(1):138-9. PMID: 2934644.

5

Jankovic J. Recent advances in the management of tics. Clin Neuropharmacol. 1986;9 Suppl 2:S100-10. PMID: 2885086.

21

Jankovic J. Whipple's disease of the central nervous system in AIDS. N Engl J Med. 1986;315(16):1029-30. PMID: 2429182.

9

Wells CR, Jankovic J. Familial spastic paraparesis and deafness. A new x-linked neurodegenerative disorder. Arch Neurol. 1986;43(9):943-6. PMID: 3741213.

104

Geraghty JJ, Jankovic J, Zetusky WJ. Association between essential tremor and Parkinson's disease. Ann Neurol. 1985;17(4):329-33. PMID: 4004153.

31

Jankovic J, Glass JP. Metoclopramide-induced phantom dyskinesia. Neurology. 1985;35(3):432-5. PMID: 3974906.

85

Jankovic J, Kirkpatrick JB, Blomquist KA, Langlais PJ, Bird ED. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology. 1985;35(2):227-34. PMID: 3969211.

7

Jankovic J, Orman J, Jansson B. Placebo-controlled study of mesulergine in Parkinson's disease. Neurology. 1985;35(2):161-5. PMID: 3881692.

38

Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology. 1985;35(3):296-9. PMID: 3974887.

12

Jankovic J. Long-term use of dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 1985;8(2):131-40. PMID: 3891082.

13

Jankovic J. Progressive supranuclear palsy: paraneoplastic effect of bronchial carcinoma. Neurology. 1985;35(3):446-7. PMID: 3974912.

74

Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol. 1985;17(5):505-9. PMID: 4004173.

212

Pettigrew LC, Jankovic J. Hemidystonia: a report of 22 patients and a review of the literature. J Neurol Neurosurg Psychiatry. 1985;48(7):650-7. PMID: 4031909.

49

Reshef E, Greenberg SB, Jankovic J. Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. J Neurol Neurosurg Psychiatry. 1985;48(2):122-7. PMID: 3884741.

69

Spitz MC, Jankovic J, Killian JM. Familial tic disorder, parkinsonism, motor neuron disease, and acanthocytosis: a new syndrome. Neurology. 1985;35(3):366-70. PMID: 3974894.

234

Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology. 1985;35(4):522-6. PMID: 3982637.

10

Zetusky WJ, Jankovic J. Laterality and symptom association in Parkinson's disease. Arch Neurol. 1985;42(12):1132-3. PMID: 4062609.

22

Fahn S, Jankovic J. Practical management of dystonia. Neurol Clin. 1984;2(3):555-69. PMID: 6398405.

25

Glass JP, Jankovic J, Borit A. Hemiballism and metastatic brain tumor. Neurology. 1984;34(2):204-7. PMID: 6538010.

75

Jankovic J, Glaze DG, Frost JD, Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology. 1984;34(5):688-92. PMID: 6584743.

67

Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. 1984;16(4):371-6. PMID: 6144283.

33

Jankovic J. Progressive supranuclear palsy. Clinical and pharmacologic update. Neurol Clin. 1984;2(3):473-86. PMID: 6398402.

7

Evans BK, Jankovic J. Tuberous sclerosis and chorea. Ann Neurol. 1983;13(1):106-7. PMID: 6830155.

76

Glaze DG, Frost JD, Jr, Jankovic J. Sleep in Gilles de la Tourette's syndrome: disorder of arousal. Neurology. 1983;33(5):586-92. PMID: 6573576.

107

Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13(3):273-8. PMID: 6847139.

204

Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol. 1983;13(4):402-11. PMID: 6838174.

155

Jankovic J, Patel SC. Blepharospasm associated with brainstem lesions. Neurology. 1983;33(9):1237-40. PMID: 6684264.

26

Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology. 1983;33(4):505-7. PMID: 6339985.

17

Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol. 1983;37:277-89. PMID: 6574695.

6

Levy RS, Jankovic J. Placebo-induced conversion reaction: a neurobehavioral and EEG study of hysterical aphasia, seizure, and coma. J Abnorm Psychol. 1983;92(2):243-9. PMID: 6190852.

7

Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia and inappropriate use of neuroleptic drugs. Lancet. 1982;1(8284):1299. PMID: 6123031.

307

Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology. 1982;32(12):1335-46. PMID: 6128697.

87

Jankovic J, Havins WE, Wilkins RB. Blinking and blepharospasm. Mechanism, diagnosis, and management. Jama. 1982;248(23):3160-4. PMID: 7143695.

37

Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology. 1982;32(10):1195-7. PMID: 6889706.

8

Jankovic J. Management of motor side effects of chronic levodopa therapy. Clin Neuropharmacol. 1982;5 Suppl 1:S19-28. PMID: 7116343.

101

Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol. 1982;11(1):41-7. PMID: 6460467.

0     

 

Burke RE, Fahn S, Jankovic J. Tardive dystonia: a persistent dystonia due to antipsychotic drugs. Neurology. 1981;31(4 (Part 2)):79.

31

Jankovic J, Frost JD, Jr. Quantitative assessment of parkinsonian and essential tremor: clinical application of triaxial accelerometry. Neurology. 1981;31(10):1235-40. PMID: 7202133.

36

Jankovic J. Drug-induced and other orofacial-cervical dyskinesias. Ann Intern Med. 1981;94(6):788-93. PMID: 7015951.

0     

Jankovic J. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency? Ann Neurol. 1981;10(1):64-5. PMID: 7271235.

38

Porter M, Jankovic J. Benign coital cephalalgia. Differential diagnosis and treatment. Arch Neurol. 1981;38(11):710-2. PMID: 7305700.

16

Ashizawa T, Patten BM, Jankovic J. Meige's syndrome. South Med J. 1980;73(7):863-6. PMID: 7384844.

4

Jankovic J, Derman H, Armstrong D. Haemorrhagic complications of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1980;43(1):76-81. PMID: 7354362.

90

Jankovic J, Fahn S. Physiologic and pathologic tremors. Diagnosis, mechanism, and management. Ann Intern Med. 1980;93(3):460-5. PMID: 7001967.

15

Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979;6(3):227-31. PMID: 534421.

2

Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: a new syndrome. Trans Am Neurol Assoc. 1978;103:116-8. PMID: 757033.

0     

 

Jankovic J, Rivera VM. Hereditary myoclonus and progressive spinal muscular atrophy: A new syndrome. Ann Neurol. 1978;4(2):170-1.